3–6 months	0	1.0	2	Medicines and Healthcare products Regulatory Agency (MHRA) guidance (2011) advises that 'prescribers should review the safety and efficacy of pioglitazone in individuals after 3–6 months of treatment to ensure that only patients who are deriving benefit continue to be treated'.	Medicines and Healthcare products Regulatory Agency (MHRA) guidance (2011) advises that 'prescribers should review the safety and efficacy of pioglitazone in individuals after 3–6 months of treatment to ensure that only patients who are deriving benefit continue to be treated'.	
ace inhibitor	0	1.0	2	Caribbean family origin should be an ACE inhibitor plus either a diuretic or a generic calcium-channel blocker.	Caribbean family origin should be an ACE inhibitor plus either a diuretic or a generic calcium-channel blocker.	
advise adults	0	1.0	2	Advise adults with type 2 diabetes that limited substitution of sucrose-containing foods for other carbohydrate in the meal plan is allowable, but that they should take care to avoid excess energy intake.	Advise adults with type 2 diabetes that limited substitution of sucrose-containing foods for other carbohydrate in the meal plan is allowable, but that they should take care to avoid excess energy intake.	
antiplatelet therapy	0	1.0	2	Do not offer antiplatelet therapy (aspirin or clopidogrel) for adults with type 2 diabetes without cardiovascular disease.	Do not offer antiplatelet therapy (aspirin or clopidogrel) for adults with type 2 diabetes without cardiovascular disease.	
bariatric surgery	0	1.0	2	For recommendations on bariatric surgery for people with recent-onset type 2 diabetes, see the section on bariatric surgery for people with recent-onset type 2 diabetes in the NICE guideline on obesity.	For recommendations on bariatric surgery for people with recent-onset type 2 diabetes, see the section on bariatric surgery for people with recent-onset type 2 diabetes in the NICE guideline on obesity.	
carbohydrate content	0	1.0	2	When adults with type 2 diabetes are admitted to hospital as inpatients or to any other care setting, implement a meal planning system that provides consistency in the carbohydrate content of meals and snacks.	When adults with type 2 diabetes are admitted to hospital as inpatients or to any other care setting, implement a meal planning system that provides consistency in the carbohydrate content of meals and snacks.	
care advice	0	1.0	2	In adults with type 2 diabetes, only offer a GLP-1 mimetic in combination with insulin with specialist care advice and ongoing support from a consultant-led multidisciplinary team .	In adults with type 2 diabetes, only offer a GLP-1 mimetic in combination with insulin with specialist care advice and ongoing support from a consultant-led multidisciplinary team .	
consultant-led multidisciplinary	0	1.0	2	In adults with type 2 diabetes, only offer a GLP-1 mimetic in combination with insulin with specialist care advice and ongoing support from a consultant-led multidisciplinary team .	In adults with type 2 diabetes, only offer a GLP-1 mimetic in combination with insulin with specialist care advice and ongoing support from a consultant-led multidisciplinary team .	
current medical	0	1.0	2	Take the Driver and Vehicle Licensing Agency (DVLA) At a glance guide to the current medical standards of fitness to drive into account when offering self-monitoring of blood glucose levels for adults with type 2 diabetes.	Take the Driver and Vehicle Licensing Agency (DVLA) At a glance guide to the current medical standards of fitness to drive into account when offering self-monitoring of blood glucose levels for adults with type 2 diabetes.	
details medicines	0	1.0	0	
diabetes type	0	1.0	0	
dipeptidyl peptidase-4	0	1.0	2	In adults with type 2 diabetes, if metformin is contraindicated or not tolerated, consider initial drug treatment with: a dipeptidyl peptidase-4 (DPP-4) inhibitor or pioglitazone or a sulfonylurea.	In adults with type 2 diabetes, if metformin is contraindicated or not tolerated, consider initial drug treatment with: a dipeptidyl peptidase-4 (DPP-4) inhibitor or pioglitazone or a sulfonylurea.	
disease offer	0	1.0	0	
energy intake	0	1.0	2	Advise adults with type 2 diabetes that limited substitution of sucrose-containing foods for other carbohydrate in the meal plan is allowable, but that they should take care to avoid excess energy intake.	Advise adults with type 2 diabetes that limited substitution of sucrose-containing foods for other carbohydrate in the meal plan is allowable, but that they should take care to avoid excess energy intake.	
estimated glomerular	0	1.0	2	In adults with type 2 diabetes, review the dose of metformin if the estimated glomerular filtration rate (eGFR) is below 45 ml minute m2:	In adults with type 2 diabetes, review the dose of metformin if the estimated glomerular filtration rate (eGFR) is below 45 ml minute m2:	
excess energy	0	1.0	2	Advise adults with type 2 diabetes that limited substitution of sucrose-containing foods for other carbohydrate in the meal plan is allowable, but that they should take care to avoid excess energy intake.	Advise adults with type 2 diabetes that limited substitution of sucrose-containing foods for other carbohydrate in the meal plan is allowable, but that they should take care to avoid excess energy intake.	
filtration rate	0	1.0	2	In adults with type 2 diabetes, review the dose of metformin if the estimated glomerular filtration rate (eGFR) is below 45 ml minute m2:	In adults with type 2 diabetes, review the dose of metformin if the estimated glomerular filtration rate (eGFR) is below 45 ml minute m2:	
generic calcium-channel	0	1.0	2	Caribbean family origin should be an ACE inhibitor plus either a diuretic or a generic calcium-channel blocker.	Caribbean family origin should be an ACE inhibitor plus either a diuretic or a generic calcium-channel blocker.	
glance guide	0	1.0	2	Take the Driver and Vehicle Licensing Agency (DVLA) At a glance guide to the current medical standards of fitness to drive into account when offering self-monitoring of blood glucose levels for adults with type 2 diabetes.	Take the Driver and Vehicle Licensing Agency (DVLA) At a glance guide to the current medical standards of fitness to drive into account when offering self-monitoring of blood glucose levels for adults with type 2 diabetes.	
glomerular filtration	0	1.0	2	In adults with type 2 diabetes, review the dose of metformin if the estimated glomerular filtration rate (eGFR) is below 45 ml minute m2:	In adults with type 2 diabetes, review the dose of metformin if the estimated glomerular filtration rate (eGFR) is below 45 ml minute m2:	
glp-1 mimetic	0	1.0	2	In adults with type 2 diabetes, only offer a GLP-1 mimetic in combination with insulin with specialist care advice and ongoing support from a consultant-led multidisciplinary team .	In adults with type 2 diabetes, only offer a GLP-1 mimetic in combination with insulin with specialist care advice and ongoing support from a consultant-led multidisciplinary team .	
hba1c targets	0	1.0	2	For guidance on HbA1c targets for women with type 2 diabetes who are pregnant or planning to become pregnant, see the NICE guideline on diabetes in pregnancy.	For guidance on HbA1c targets for women with type 2 diabetes who are pregnant or planning to become pregnant, see the NICE guideline on diabetes in pregnancy.	
heart failure	0	1.0	2	In adults with type 2 diabetes, do not offer or continue pioglitazone if they have any of the following: heart failure or history of heart failure	In adults with type 2 diabetes, do not offer or continue pioglitazone if they have any of the following: heart failure or history of heart failure	
independent assessors	0	1.0	2	It is quality assured, and reviewed by trained, competent, independent assessors who measure it against criteria that ensure consistency.	It is quality assured, and reviewed by trained, competent, independent assessors who measure it against criteria that ensure consistency.	
informed discussion	0	1.0	2	A calcium-channel blocker should be the first-line antihypertensive drug treatment for a woman for whom, after an informed discussion, it is agreed there is a possibility of her becoming pregnant.	A calcium-channel blocker should be the first-line antihypertensive drug treatment for a woman for whom, after an informed discussion, it is agreed there is a possibility of her becoming pregnant.	
intravenous corticosteroids	0	1.0	2	Consider short-term self-monitoring of blood glucose levels in adults with type 2 diabetes (and review treatment as necessary): when starting treatment with oral or intravenous corticosteroids or to confirm suspected hypoglycaemia.	Consider short-term self-monitoring of blood glucose levels in adults with type 2 diabetes (and review treatment as necessary): when starting treatment with oral or intravenous corticosteroids or to confirm suspected hypoglycaemia.	
licensing agency	0	1.0	2	Take the Driver and Vehicle Licensing Agency (DVLA) At a glance guide to the current medical standards of fitness to drive into account when offering self-monitoring of blood glucose levels for adults with type 2 diabetes.	Take the Driver and Vehicle Licensing Agency (DVLA) At a glance guide to the current medical standards of fitness to drive into account when offering self-monitoring of blood glucose levels for adults with type 2 diabetes.	
limited substitution	0	1.0	2	Advise adults with type 2 diabetes that limited substitution of sucrose-containing foods for other carbohydrate in the meal plan is allowable, but that they should take care to avoid excess energy intake.	Advise adults with type 2 diabetes that limited substitution of sucrose-containing foods for other carbohydrate in the meal plan is allowable, but that they should take care to avoid excess energy intake.	
meal plan	0	1.0	4	Advise adults with type 2 diabetes that limited substitution of sucrose-containing foods for other carbohydrate in the meal plan is allowable, but that they should take care to avoid excess energy intake.	When adults with type 2 diabetes are admitted to hospital as inpatients or to any other care setting, implement a meal planning system that provides consistency in the carbohydrate content of meals and snacks.	Advise adults with type 2 diabetes that limited substitution of sucrose-containing foods for other carbohydrate in the meal plan is allowable, but that they should take care to avoid excess energy intake.	When adults with type 2 diabetes are admitted to hospital as inpatients or to any other care setting, implement a meal planning system that provides consistency in the carbohydrate content of meals and snacks.	
meal planning	0	1.0	2	When adults with type 2 diabetes are admitted to hospital as inpatients or to any other care setting, implement a meal planning system that provides consistency in the carbohydrate content of meals and snacks.	When adults with type 2 diabetes are admitted to hospital as inpatients or to any other care setting, implement a meal planning system that provides consistency in the carbohydrate content of meals and snacks.	
measure blood	0	1.0	2	Measure blood pressure at least annually in an adult with type 2 diabetes without previously diagnosed hypertension or renal disease	Measure blood pressure at least annually in an adult with type 2 diabetes without previously diagnosed hypertension or renal disease	
medical standards	0	1.0	2	Take the Driver and Vehicle Licensing Agency (DVLA) At a glance guide to the current medical standards of fitness to drive into account when offering self-monitoring of blood glucose levels for adults with type 2 diabetes.	Take the Driver and Vehicle Licensing Agency (DVLA) At a glance guide to the current medical standards of fitness to drive into account when offering self-monitoring of blood glucose levels for adults with type 2 diabetes.	
minute m2	0	1.0	2	In adults with type 2 diabetes, review the dose of metformin if the estimated glomerular filtration rate (eGFR) is below 45 ml minute m2:	In adults with type 2 diabetes, review the dose of metformin if the estimated glomerular filtration rate (eGFR) is below 45 ml minute m2:	
ml minute	0	1.0	2	In adults with type 2 diabetes, review the dose of metformin if the estimated glomerular filtration rate (eGFR) is below 45 ml minute m2:	In adults with type 2 diabetes, review the dose of metformin if the estimated glomerular filtration rate (eGFR) is below 45 ml minute m2:	
modified-release metformin	0	1.0	2	If an adult with type 2 diabetes experiences gastrointestinal side effects with standard-release metformin, consider a trial of modified-release metformin.	If an adult with type 2 diabetes experiences gastrointestinal side effects with standard-release metformin, consider a trial of modified-release metformin.	
multidisciplinary team	0	1.0	2	In adults with type 2 diabetes, only offer a GLP-1 mimetic in combination with insulin with specialist care advice and ongoing support from a consultant-led multidisciplinary team .	In adults with type 2 diabetes, only offer a GLP-1 mimetic in combination with insulin with specialist care advice and ongoing support from a consultant-led multidisciplinary team .	
offer standard-release	0	1.0	2	Offer standard-release metformin as the initial drug treatment for adults with type 2 diabetes.	Offer standard-release metformin as the initial drug treatment for adults with type 2 diabetes.	
ongoing support	0	1.0	2	In adults with type 2 diabetes, only offer a GLP-1 mimetic in combination with insulin with specialist care advice and ongoing support from a consultant-led multidisciplinary team .	In adults with type 2 diabetes, only offer a GLP-1 mimetic in combination with insulin with specialist care advice and ongoing support from a consultant-led multidisciplinary team .	
planning system	0	1.0	2	When adults with type 2 diabetes are admitted to hospital as inpatients or to any other care setting, implement a meal planning system that provides consistency in the carbohydrate content of meals and snacks.	When adults with type 2 diabetes are admitted to hospital as inpatients or to any other care setting, implement a meal planning system that provides consistency in the carbohydrate content of meals and snacks.	
pressure control	0	1.0	2	For an adult with type 2 diabetes on antihypertensive drug treatment when diabetes is diagnosed, review blood pressure control and medications used.	For an adult with type 2 diabetes on antihypertensive drug treatment when diabetes is diagnosed, review blood pressure control and medications used.	
preventive lifestyle	0	1.0	2	Offer and reinforce preventive lifestyle advice.	Offer and reinforce preventive lifestyle advice.	
product characteristics	0	1.0	2	Known risk factors for these conditions, including increased age, should be carefully evaluated before treatment: see the manufacturers' summaries of product characteristics for details	Known risk factors for these conditions, including increased age, should be carefully evaluated before treatment: see the manufacturers' summaries of product characteristics for details	
recent-onset type	0	1.0	2	For recommendations on bariatric surgery for people with recent-onset type 2 diabetes, see the section on bariatric surgery for people with recent-onset type 2 diabetes in the NICE guideline on obesity.	For recommendations on bariatric surgery for people with recent-onset type 2 diabetes, see the section on bariatric surgery for people with recent-onset type 2 diabetes in the NICE guideline on obesity.	
renal disease	0	1.0	2	Measure blood pressure at least annually in an adult with type 2 diabetes without previously diagnosed hypertension or renal disease	Measure blood pressure at least annually in an adult with type 2 diabetes without previously diagnosed hypertension or renal disease	
risk factors	0	1.0	2	Known risk factors for these conditions, including increased age, should be carefully evaluated before treatment: see the manufacturers' summaries of product characteristics for details	Known risk factors for these conditions, including increased age, should be carefully evaluated before treatment: see the manufacturers' summaries of product characteristics for details	
short-term self-monitoring	0	1.0	2	Consider short-term self-monitoring of blood glucose levels in adults with type 2 diabetes (and review treatment as necessary): when starting treatment with oral or intravenous corticosteroids or to confirm suspected hypoglycaemia.	Consider short-term self-monitoring of blood glucose levels in adults with type 2 diabetes (and review treatment as necessary): when starting treatment with oral or intravenous corticosteroids or to confirm suspected hypoglycaemia.	
specialist care	0	1.0	2	In adults with type 2 diabetes, only offer a GLP-1 mimetic in combination with insulin with specialist care advice and ongoing support from a consultant-led multidisciplinary team .	In adults with type 2 diabetes, only offer a GLP-1 mimetic in combination with insulin with specialist care advice and ongoing support from a consultant-led multidisciplinary team .	
sucrose-containing foods	0	1.0	2	Advise adults with type 2 diabetes that limited substitution of sucrose-containing foods for other carbohydrate in the meal plan is allowable, but that they should take care to avoid excess energy intake.	Advise adults with type 2 diabetes that limited substitution of sucrose-containing foods for other carbohydrate in the meal plan is allowable, but that they should take care to avoid excess energy intake.	
suspected hypoglycaemia	0	1.0	2	Consider short-term self-monitoring of blood glucose levels in adults with type 2 diabetes (and review treatment as necessary): when starting treatment with oral or intravenous corticosteroids or to confirm suspected hypoglycaemia.	Consider short-term self-monitoring of blood glucose levels in adults with type 2 diabetes (and review treatment as necessary): when starting treatment with oral or intravenous corticosteroids or to confirm suspected hypoglycaemia.	
vehicle licensing	0	1.0	2	Take the Driver and Vehicle Licensing Agency (DVLA) At a glance guide to the current medical standards of fitness to drive into account when offering self-monitoring of blood glucose levels for adults with type 2 diabetes.	Take the Driver and Vehicle Licensing Agency (DVLA) At a glance guide to the current medical standards of fitness to drive into account when offering self-monitoring of blood glucose levels for adults with type 2 diabetes.	
visual impairment	0	1.0	2	Take into account any disabilities, including visual impairment, when planning and delivering care for adults with type 2 diabetes.	Take into account any disabilities, including visual impairment, when planning and delivering care for adults with type 2 diabetes.	
cardiovascular disease	0	0.9242	4	Do not offer antiplatelet therapy (aspirin or clopidogrel) for adults with type 2 diabetes without cardiovascular disease.	For guidance on the primary and secondary prevention of cardiovascular disease in adults with type 2 diabetes, see the NICE guidelines on cardiovascular disease and myocardial infarction.	Do not offer antiplatelet therapy (aspirin or clopidogrel) for adults with type 2 diabetes without cardiovascular disease.	For guidance on the primary and secondary prevention of cardiovascular disease in adults with type 2 diabetes, see the NICE guidelines on cardiovascular disease and myocardial infarction.	
review treatment	0	0.9242	4	Consider short-term self-monitoring of blood glucose levels in adults with type 2 diabetes (and review treatment as necessary): when starting treatment with oral or intravenous corticosteroids or to confirm suspected hypoglycaemia.	If an adult with type 2 diabetes is symptomatically hyperglycaemic, consider insulin (see recommendations – ) or a sulfonylurea, and review treatment when blood glucose control has been achieved.	Consider short-term self-monitoring of blood glucose levels in adults with type 2 diabetes (and review treatment as necessary): when starting treatment with oral or intravenous corticosteroids or to confirm suspected hypoglycaemia.	If an adult with type 2 diabetes is symptomatically hyperglycaemic, consider insulin (see recommendations – ) or a sulfonylurea, and review treatment when blood glucose control has been achieved.	
calcium-channel blocker	0	0.8484	4	Caribbean family origin should be an ACE inhibitor plus either a diuretic or a generic calcium-channel blocker.	A calcium-channel blocker should be the first-line antihypertensive drug treatment for a woman for whom, after an informed discussion, it is agreed there is a possibility of her becoming pregnant.	Caribbean family origin should be an ACE inhibitor plus either a diuretic or a generic calcium-channel blocker.	A calcium-channel blocker should be the first-line antihypertensive drug treatment for a woman for whom, after an informed discussion, it is agreed there is a possibility of her becoming pregnant.	
gastrointestinal side	0	0.8484	4	Gradually increase the dose of standard-release metformin over several weeks to minimise the risk of gastrointestinal side effects in adults with type 2 diabetes.	If an adult with type 2 diabetes experiences gastrointestinal side effects with standard-release metformin, consider a trial of modified-release metformin.	Gradually increase the dose of standard-release metformin over several weeks to minimise the risk of gastrointestinal side effects in adults with type 2 diabetes.	If an adult with type 2 diabetes experiences gastrointestinal side effects with standard-release metformin, consider a trial of modified-release metformin.	
side effects	0	0.8484	4	Gradually increase the dose of standard-release metformin over several weeks to minimise the risk of gastrointestinal side effects in adults with type 2 diabetes.	If an adult with type 2 diabetes experiences gastrointestinal side effects with standard-release metformin, consider a trial of modified-release metformin.	Gradually increase the dose of standard-release metformin over several weeks to minimise the risk of gastrointestinal side effects in adults with type 2 diabetes.	If an adult with type 2 diabetes experiences gastrointestinal side effects with standard-release metformin, consider a trial of modified-release metformin.	
blood pressure	0	0.8399	6	Measure blood pressure at least annually in an adult with type 2 diabetes without previously diagnosed hypertension or renal disease	For an adult with type 2 diabetes on antihypertensive drug treatment when diabetes is diagnosed, review blood pressure control and medications used.	Repeat blood pressure measurements within: 1 month if blood pressure is higher than 150 90 mmHg 2 months if blood pressure is higher than 140 80 mmHg 2 months if blood pressure is higher than 130 80 mmHg and there is kidney, eye or cerebrovascular damage.	Measure blood pressure at least annually in an adult with type 2 diabetes without previously diagnosed hypertension or renal disease	For an adult with type 2 diabetes on antihypertensive drug treatment when diabetes is diagnosed, review blood pressure control and medications used.	Repeat blood pressure measurements within: 1 month if blood pressure is higher than 150 90 mmHg 2 months if blood pressure is higher than 140 80 mmHg 2 months if blood pressure is higher than 130 80 mmHg and there is kidney, eye or cerebrovascular damage.	
5–10percent individualise	0	0.8214	0	
alcohol intake	0	0.8214	2	Individualise recommendations for carbohydrate and alcohol intake, and meal patterns	Individualise recommendations for carbohydrate and alcohol intake, and meal patterns	
balanced eating	0	0.8214	2	Emphasise advice on healthy balanced eating that is applicable to the general population when providing advice to adults with type 2 diabetes	Emphasise advice on healthy balanced eating that is applicable to the general population when providing advice to adults with type 2 diabetes	
body weight	0	0.8214	2	For adults with type 2 diabetes who are overweight, set an initial body weight loss target of 5–10percent	For adults with type 2 diabetes who are overweight, set an initial body weight loss target of 5–10percent	
emphasise advice	0	0.8214	2	Emphasise advice on healthy balanced eating that is applicable to the general population when providing advice to adults with type 2 diabetes	Emphasise advice on healthy balanced eating that is applicable to the general population when providing advice to adults with type 2 diabetes	
general population	1	0.8214	2	Emphasise advice on healthy balanced eating that is applicable to the general population when providing advice to adults with type 2 diabetes	Emphasise advice on healthy balanced eating that is applicable to the general population when providing advice to adults with type 2 diabetes	
healthy balanced	0	0.8214	2	Emphasise advice on healthy balanced eating that is applicable to the general population when providing advice to adults with type 2 diabetes	Emphasise advice on healthy balanced eating that is applicable to the general population when providing advice to adults with type 2 diabetes	
individualise recommendations	0	0.8214	2	Individualise recommendations for carbohydrate and alcohol intake, and meal patterns	Individualise recommendations for carbohydrate and alcohol intake, and meal patterns	
initial body	0	0.8214	2	For adults with type 2 diabetes who are overweight, set an initial body weight loss target of 5–10percent	For adults with type 2 diabetes who are overweight, set an initial body weight loss target of 5–10percent	
insulin secretagogue	0	0.8214	2	Reducing the risk of hypoglycaemia should be a particular aim for a person using insulin or an insulin secretagogue.	Reducing the risk of hypoglycaemia should be a particular aim for a person using insulin or an insulin secretagogue.	
loss target	0	0.8214	2	For adults with type 2 diabetes who are overweight, set an initial body weight loss target of 5–10percent	For adults with type 2 diabetes who are overweight, set an initial body weight loss target of 5–10percent	
meal patterns	0	0.8214	2	Individualise recommendations for carbohydrate and alcohol intake, and meal patterns	Individualise recommendations for carbohydrate and alcohol intake, and meal patterns	
insulin-based treatment	0	0.8086	4	In adults with type 2 diabetes, if dual therapy with metformin and another oral drug (see recommendation ) has not continued to control HbA1c to below the person's individually agreed threshold for intensification, consider either: triple therapy with: metformin, a DPP-4 inhibitor and a sulfonylurea or metformin, pioglitazone and a sulfonylurea or starting insulin-based treatment (see recommendations – ).	In adults with type 2 diabetes, if metformin is contraindicated or not tolerated, and if dual therapy with 2 oral drugs (see recommendation ) has not continued to control HbA1c to below the person's individually agreed threshold for intensification, consider insulin-based treatment (see recommendations – ).	In adults with type 2 diabetes, if dual therapy with metformin and another oral drug (see recommendation ) has not continued to control HbA1c to below the person's individually agreed threshold for intensification, consider either: triple therapy with: metformin, a DPP-4 inhibitor and a sulfonylurea or metformin, pioglitazone and a sulfonylurea or starting insulin-based treatment (see recommendations – ).	In adults with type 2 diabetes, if metformin is contraindicated or not tolerated, and if dual therapy with 2 oral drugs (see recommendation ) has not continued to control HbA1c to below the person's individually agreed threshold for intensification, consider insulin-based treatment (see recommendations – ).	
mmol mol	0	0.7964	6	For adults with type 2 diabetes managed either by lifestyle and diet, or by lifestyle and diet combined with a single drug not associated with hypoglycaemia, support the person to aim for an HbA1c level of 48 mmol mol ( percent)	For adults on a drug associated with hypoglycaemia, support the person to aim for an HbA1c level of 53 mmol mol ( percent).	In adults with type 2 diabetes, if HbA1c levels are not adequately controlled by a single drug and rise to 58 mmol mol ( percent) or higher: reinforce advice about diet, lifestyle and adherence to drug treatment and support the person to aim for an HbA1c level of 53 mmol mol ( percent) and intensify drug treatment.	For adults with type 2 diabetes managed either by lifestyle and diet, or by lifestyle and diet combined with a single drug not associated with hypoglycaemia, support the person to aim for an HbA1c level of 48 mmol mol ( percent)	For adults on a drug associated with hypoglycaemia, support the person to aim for an HbA1c level of 53 mmol mol ( percent).	In adults with type 2 diabetes, if HbA1c levels are not adequately controlled by a single drug and rise to 58 mmol mol ( percent) or higher: reinforce advice about diet, lifestyle and adherence to drug treatment and support the person to aim for an HbA1c level of 53 mmol mol ( percent) and intensify drug treatment.	
low hba1c	0	0.7712	2	Be aware that there are other possible reasons for a low HbA1c level, for example, deteriorating renal function or sudden weight loss.	Be aware that there are other possible reasons for a low HbA1c level, for example, deteriorating renal function or sudden weight loss.	
renal function	0	0.7712	2	Be aware that there are other possible reasons for a low HbA1c level, for example, deteriorating renal function or sudden weight loss.	Be aware that there are other possible reasons for a low HbA1c level, for example, deteriorating renal function or sudden weight loss.	
sudden weight	0	0.7712	2	Be aware that there are other possible reasons for a low HbA1c level, for example, deteriorating renal function or sudden weight loss.	Be aware that there are other possible reasons for a low HbA1c level, for example, deteriorating renal function or sudden weight loss.	
standard-release metformin	0	0.7598	6	Offer standard-release metformin as the initial drug treatment for adults with type 2 diabetes.	Gradually increase the dose of standard-release metformin over several weeks to minimise the risk of gastrointestinal side effects in adults with type 2 diabetes.	If an adult with type 2 diabetes experiences gastrointestinal side effects with standard-release metformin, consider a trial of modified-release metformin.	Offer standard-release metformin as the initial drug treatment for adults with type 2 diabetes.	Gradually increase the dose of standard-release metformin over several weeks to minimise the risk of gastrointestinal side effects in adults with type 2 diabetes.	If an adult with type 2 diabetes experiences gastrointestinal side effects with standard-release metformin, consider a trial of modified-release metformin.	
hypoglycaemic episodes	0	0.756	2	Do not routinely offer self-monitoring of blood glucose levels for adults with type 2 diabetes unless: the person is on insulin or there is evidence of hypoglycaemic episodes or the person is on oral medication that may increase their risk of hypoglycaemia while driving or operating machinery or	Do not routinely offer self-monitoring of blood glucose levels for adults with type 2 diabetes unless: the person is on insulin or there is evidence of hypoglycaemic episodes or the person is on oral medication that may increase their risk of hypoglycaemia while driving or operating machinery or	
oral medication	0	0.756	2	Do not routinely offer self-monitoring of blood glucose levels for adults with type 2 diabetes unless: the person is on insulin or there is evidence of hypoglycaemic episodes or the person is on oral medication that may increase their risk of hypoglycaemia while driving or operating machinery or	Do not routinely offer self-monitoring of blood glucose levels for adults with type 2 diabetes unless: the person is on insulin or there is evidence of hypoglycaemic episodes or the person is on oral medication that may increase their risk of hypoglycaemia while driving or operating machinery or	
oral drug	0	0.7275	6	In adults with type 2 diabetes, if dual therapy with metformin and another oral drug (see recommendation ) has not continued to control HbA1c to below the person's individually agreed threshold for intensification, consider either: triple therapy with: metformin, a DPP-4 inhibitor and a sulfonylurea or metformin, pioglitazone and a sulfonylurea or starting insulin-based treatment (see recommendations – ).	If triple therapy with metformin and 2 other oral drugs (see recommendation ) is not effective, not tolerated or contraindicated, consider combination therapy with metformin, a sulfonylurea and a glucagon-like peptide-1 (GLP-1) mimetic for adults with type 2 diabetes who: have a BMI of 35 kg m2 or higher (adjust accordingly for people from black, Asian and other minority ethnic groups) and specific psychological or other medical problems associated with obesity or have a BMI lower than 35 kg m2and: for whom insulin therapy would have significant occupational implications or weight loss would benefit other significant obesity-related comorbidities.	In adults with type 2 diabetes, if metformin is contraindicated or not tolerated, and if dual therapy with 2 oral drugs (see recommendation ) has not continued to control HbA1c to below the person's individually agreed threshold for intensification, consider insulin-based treatment (see recommendations – ).	In adults with type 2 diabetes, if dual therapy with metformin and another oral drug (see recommendation ) has not continued to control HbA1c to below the person's individually agreed threshold for intensification, consider either: triple therapy with: metformin, a DPP-4 inhibitor and a sulfonylurea or metformin, pioglitazone and a sulfonylurea or starting insulin-based treatment (see recommendations – ).	If triple therapy with metformin and 2 other oral drugs (see recommendation ) is not effective, not tolerated or contraindicated, consider combination therapy with metformin, a sulfonylurea and a glucagon-like peptide-1 (GLP-1) mimetic for adults with type 2 diabetes who: have a BMI of 35 kg m2 or higher (adjust accordingly for people from black, Asian and other minority ethnic groups) and specific psychological or other medical problems associated with obesity or have a BMI lower than 35 kg m2and: for whom insulin therapy would have significant occupational implications or weight loss would benefit other significant obesity-related comorbidities.	In adults with type 2 diabetes, if metformin is contraindicated or not tolerated, and if dual therapy with 2 oral drugs (see recommendation ) has not continued to control HbA1c to below the person's individually agreed threshold for intensification, consider insulin-based treatment (see recommendations – ).	
diabetes care	0	0.7174	2	Adopt an individualised approach to diabetes care that is tailored to the needs and circumstances of adults with type 2 diabetes, taking into account their personal preferences, comorbidities, risks from polypharmacy, and their ability to benefit from long-term interventions because of reduced life expectancy.	Adopt an individualised approach to diabetes care that is tailored to the needs and circumstances of adults with type 2 diabetes, taking into account their personal preferences, comorbidities, risks from polypharmacy, and their ability to benefit from long-term interventions because of reduced life expectancy.	
long-term interventions	0	0.7174	2	Adopt an individualised approach to diabetes care that is tailored to the needs and circumstances of adults with type 2 diabetes, taking into account their personal preferences, comorbidities, risks from polypharmacy, and their ability to benefit from long-term interventions because of reduced life expectancy.	Adopt an individualised approach to diabetes care that is tailored to the needs and circumstances of adults with type 2 diabetes, taking into account their personal preferences, comorbidities, risks from polypharmacy, and their ability to benefit from long-term interventions because of reduced life expectancy.	
personal preferences	0	0.7174	2	Adopt an individualised approach to diabetes care that is tailored to the needs and circumstances of adults with type 2 diabetes, taking into account their personal preferences, comorbidities, risks from polypharmacy, and their ability to benefit from long-term interventions because of reduced life expectancy.	Adopt an individualised approach to diabetes care that is tailored to the needs and circumstances of adults with type 2 diabetes, taking into account their personal preferences, comorbidities, risks from polypharmacy, and their ability to benefit from long-term interventions because of reduced life expectancy.	
oral drugs	0	0.7121	4	If triple therapy with metformin and 2 other oral drugs (see recommendation ) is not effective, not tolerated or contraindicated, consider combination therapy with metformin, a sulfonylurea and a glucagon-like peptide-1 (GLP-1) mimetic for adults with type 2 diabetes who: have a BMI of 35 kg m2 or higher (adjust accordingly for people from black, Asian and other minority ethnic groups) and specific psychological or other medical problems associated with obesity or have a BMI lower than 35 kg m2and: for whom insulin therapy would have significant occupational implications or weight loss would benefit other significant obesity-related comorbidities.	In adults with type 2 diabetes, if metformin is contraindicated or not tolerated, and if dual therapy with 2 oral drugs (see recommendation ) has not continued to control HbA1c to below the person's individually agreed threshold for intensification, consider insulin-based treatment (see recommendations – ).	If triple therapy with metformin and 2 other oral drugs (see recommendation ) is not effective, not tolerated or contraindicated, consider combination therapy with metformin, a sulfonylurea and a glucagon-like peptide-1 (GLP-1) mimetic for adults with type 2 diabetes who: have a BMI of 35 kg m2 or higher (adjust accordingly for people from black, Asian and other minority ethnic groups) and specific psychological or other medical problems associated with obesity or have a BMI lower than 35 kg m2and: for whom insulin therapy would have significant occupational implications or weight loss would benefit other significant obesity-related comorbidities.	In adults with type 2 diabetes, if metformin is contraindicated or not tolerated, and if dual therapy with 2 oral drugs (see recommendation ) has not continued to control HbA1c to below the person's individually agreed threshold for intensification, consider insulin-based treatment (see recommendations – ).	
caribbean family	0	0.7034	4	African or Caribbean family origin, or women for whom there is a possibility of becoming pregnant.	Caribbean family origin should be an ACE inhibitor plus either a diuretic or a generic calcium-channel blocker.	African or Caribbean family origin, or women for whom there is a possibility of becoming pregnant.	Caribbean family origin should be an ACE inhibitor plus either a diuretic or a generic calcium-channel blocker.	
family origin	0	0.7034	4	African or Caribbean family origin, or women for whom there is a possibility of becoming pregnant.	Caribbean family origin should be an ACE inhibitor plus either a diuretic or a generic calcium-channel blocker.	African or Caribbean family origin, or women for whom there is a possibility of becoming pregnant.	Caribbean family origin should be an ACE inhibitor plus either a diuretic or a generic calcium-channel blocker.	
first-line antihypertensive	0	0.7034	4	First-line antihypertensive drug treatment should be a once-daily, generic angiotensin-converting enzyme (ACE) inhibitor	A calcium-channel blocker should be the first-line antihypertensive drug treatment for a woman for whom, after an informed discussion, it is agreed there is a possibility of her becoming pregnant.	First-line antihypertensive drug treatment should be a once-daily, generic angiotensin-converting enzyme (ACE) inhibitor	A calcium-channel blocker should be the first-line antihypertensive drug treatment for a woman for whom, after an informed discussion, it is agreed there is a possibility of her becoming pregnant.	
hba1c target	0	0.6988	6	Involve adults with type 2 diabetes in decisions about their individual HbA1c target	Offer lifestyle advice and drug treatment to support adults with type 2 diabetes to achieve and maintain their HbA1c target (see section )	For guidance on HbA1c targets for women with type 2 diabetes who are pregnant or planning to become pregnant, see the NICE guideline on diabetes in pregnancy.	Involve adults with type 2 diabetes in decisions about their individual HbA1c target	Offer lifestyle advice and drug treatment to support adults with type 2 diabetes to achieve and maintain their HbA1c target (see section )	For guidance on HbA1c targets for women with type 2 diabetes who are pregnant or planning to become pregnant, see the NICE guideline on diabetes in pregnancy.	
antihypertensive drug	0	0.6732	6	For an adult with type 2 diabetes on antihypertensive drug treatment when diabetes is diagnosed, review blood pressure control and medications used.	First-line antihypertensive drug treatment should be a once-daily, generic angiotensin-converting enzyme (ACE) inhibitor	A calcium-channel blocker should be the first-line antihypertensive drug treatment for a woman for whom, after an informed discussion, it is agreed there is a possibility of her becoming pregnant.	For an adult with type 2 diabetes on antihypertensive drug treatment when diabetes is diagnosed, review blood pressure control and medications used.	First-line antihypertensive drug treatment should be a once-daily, generic angiotensin-converting enzyme (ACE) inhibitor	A calcium-channel blocker should be the first-line antihypertensive drug treatment for a woman for whom, after an informed discussion, it is agreed there is a possibility of her becoming pregnant.	
adults nice	0	0.6581	2	Provide lifestyle advice (see section in this guideline and the lifestyle interventions section in hypertension in adults NICE guideline CG127) if blood	Provide lifestyle advice (see section in this guideline and the lifestyle interventions section in hypertension in adults NICE guideline CG127) if blood	
angiotensin-converting enzyme	0	0.6581	2	First-line antihypertensive drug treatment should be a once-daily, generic angiotensin-converting enzyme (ACE) inhibitor	First-line antihypertensive drug treatment should be a once-daily, generic angiotensin-converting enzyme (ACE) inhibitor	
blood type	0	0.6581	0	
generic angiotensin-converting	0	0.6581	2	First-line antihypertensive drug treatment should be a once-daily, generic angiotensin-converting enzyme (ACE) inhibitor	First-line antihypertensive drug treatment should be a once-daily, generic angiotensin-converting enzyme (ACE) inhibitor	
guideline cg127	0	0.6581	2	Provide lifestyle advice (see section in this guideline and the lifestyle interventions section in hypertension in adults NICE guideline CG127) if blood	Provide lifestyle advice (see section in this guideline and the lifestyle interventions section in hypertension in adults NICE guideline CG127) if blood	
inhibitor african	0	0.6581	0	
interventions section	0	0.6581	2	Provide lifestyle advice (see section in this guideline and the lifestyle interventions section in hypertension in adults NICE guideline CG127) if blood	Provide lifestyle advice (see section in this guideline and the lifestyle interventions section in hypertension in adults NICE guideline CG127) if blood	
lifestyle interventions	0	0.6581	2	Provide lifestyle advice (see section in this guideline and the lifestyle interventions section in hypertension in adults NICE guideline CG127) if blood	Provide lifestyle advice (see section in this guideline and the lifestyle interventions section in hypertension in adults NICE guideline CG127) if blood	
dpp-4 inhibitor	0	0.6558	6	In adults with type 2 diabetes, if initial drug treatment with metformin has not continued to control HbA1c to below the person's individually agreed threshold for intensification, consider dual therapy with: metformin and a DPP-4 inhibitor or metformin and pioglitazone or metformin and a sulfonylurea.	In adults with type 2 diabetes, if metformin is contraindicated or not tolerated and initial drug treatment has not continued to control HbA1c to below the person's individually agreed threshold for intensification, consider dual therapy with: a DPP-4 inhibitor and pioglitazone or a DPP-4 inhibitor and a sulfonylurea or pioglitazone and a sulfonylurea.	In adults with type 2 diabetes, if dual therapy with metformin and another oral drug (see recommendation ) has not continued to control HbA1c to below the person's individually agreed threshold for intensification, consider either: triple therapy with: metformin, a DPP-4 inhibitor and a sulfonylurea or metformin, pioglitazone and a sulfonylurea or starting insulin-based treatment (see recommendations – ).	In adults with type 2 diabetes, if initial drug treatment with metformin has not continued to control HbA1c to below the person's individually agreed threshold for intensification, consider dual therapy with: metformin and a DPP-4 inhibitor or metformin and pioglitazone or metformin and a sulfonylurea.	In adults with type 2 diabetes, if metformin is contraindicated or not tolerated and initial drug treatment has not continued to control HbA1c to below the person's individually agreed threshold for intensification, consider dual therapy with: a DPP-4 inhibitor and pioglitazone or a DPP-4 inhibitor and a sulfonylurea or pioglitazone and a sulfonylurea.	In adults with type 2 diabetes, if dual therapy with metformin and another oral drug (see recommendation ) has not continued to control HbA1c to below the person's individually agreed threshold for intensification, consider either: triple therapy with: metformin, a DPP-4 inhibitor and a sulfonylurea or metformin, pioglitazone and a sulfonylurea or starting insulin-based treatment (see recommendations – ).	
family members	0	0.6363	6	Offer structured education to adults with type 2 diabetes and or their family members or carers (as appropriate) at and around the time of diagnosis, with	It has specific aims and learning objectives, and supports the person and their family members and carers in developing attitudes, beliefs, knowledge and skills to self-manage diabetes.	Ensure that all members of the diabetes healthcare team are familiar with the patient-education programmes available locally, that these programmes are integrated with the rest of the care pathway, and that adults with type 2 diabetes and their family members or carers (as appropriate) have the opportunity to contribute to the design and provision of local programmes.	Offer structured education to adults with type 2 diabetes and or their family members or carers (as appropriate) at and around the time of diagnosis, with	It has specific aims and learning objectives, and supports the person and their family members and carers in developing attitudes, beliefs, knowledge and skills to self-manage diabetes.	Ensure that all members of the diabetes healthcare team are familiar with the patient-education programmes available locally, that these programmes are integrated with the rest of the care pathway, and that adults with type 2 diabetes and their family members or carers (as appropriate) have the opportunity to contribute to the design and provision of local programmes.	
healthcare products	0	0.6363	4	Medicines and Healthcare products Regulatory Agency (MHRA) guidance (2011) advises that 'prescribers should review the safety and efficacy of pioglitazone in individuals after 3–6 months of treatment to ensure that only patients who are deriving benefit continue to be treated'.	Last updated May 2017 safety (see Medicines and Healthcare products Regulatory Agency MHRA guidance) and tolerability of the drug treatment(s) the person's individual clinical circumstances, for example, comorbidities, risks from polypharmacy the person's individual preferences and needs the licensed indications or combinations available cost (if 2 drugs in the same class are appropriate, choose the option with the lowest acquisition cost).	Medicines and Healthcare products Regulatory Agency (MHRA) guidance (2011) advises that 'prescribers should review the safety and efficacy of pioglitazone in individuals after 3–6 months of treatment to ensure that only patients who are deriving benefit continue to be treated'.	Last updated May 2017 safety (see Medicines and Healthcare products Regulatory Agency MHRA guidance) and tolerability of the drug treatment(s) the person's individual clinical circumstances, for example, comorbidities, risks from polypharmacy the person's individual preferences and needs the licensed indications or combinations available cost (if 2 drugs in the same class are appropriate, choose the option with the lowest acquisition cost).	
products regulatory	0	0.6363	4	Medicines and Healthcare products Regulatory Agency (MHRA) guidance (2011) advises that 'prescribers should review the safety and efficacy of pioglitazone in individuals after 3–6 months of treatment to ensure that only patients who are deriving benefit continue to be treated'.	Last updated May 2017 safety (see Medicines and Healthcare products Regulatory Agency MHRA guidance) and tolerability of the drug treatment(s) the person's individual clinical circumstances, for example, comorbidities, risks from polypharmacy the person's individual preferences and needs the licensed indications or combinations available cost (if 2 drugs in the same class are appropriate, choose the option with the lowest acquisition cost).	Medicines and Healthcare products Regulatory Agency (MHRA) guidance (2011) advises that 'prescribers should review the safety and efficacy of pioglitazone in individuals after 3–6 months of treatment to ensure that only patients who are deriving benefit continue to be treated'.	Last updated May 2017 safety (see Medicines and Healthcare products Regulatory Agency MHRA guidance) and tolerability of the drug treatment(s) the person's individual clinical circumstances, for example, comorbidities, risks from polypharmacy the person's individual preferences and needs the licensed indications or combinations available cost (if 2 drugs in the same class are appropriate, choose the option with the lowest acquisition cost).	
regulatory agency	0	0.6363	4	Medicines and Healthcare products Regulatory Agency (MHRA) guidance (2011) advises that 'prescribers should review the safety and efficacy of pioglitazone in individuals after 3–6 months of treatment to ensure that only patients who are deriving benefit continue to be treated'.	Last updated May 2017 safety (see Medicines and Healthcare products Regulatory Agency MHRA guidance) and tolerability of the drug treatment(s) the person's individual clinical circumstances, for example, comorbidities, risks from polypharmacy the person's individual preferences and needs the licensed indications or combinations available cost (if 2 drugs in the same class are appropriate, choose the option with the lowest acquisition cost).	Medicines and Healthcare products Regulatory Agency (MHRA) guidance (2011) advises that 'prescribers should review the safety and efficacy of pioglitazone in individuals after 3–6 months of treatment to ensure that only patients who are deriving benefit continue to be treated'.	Last updated May 2017 safety (see Medicines and Healthcare products Regulatory Agency MHRA guidance) and tolerability of the drug treatment(s) the person's individual clinical circumstances, for example, comorbidities, risks from polypharmacy the person's individual preferences and needs the licensed indications or combinations available cost (if 2 drugs in the same class are appropriate, choose the option with the lowest acquisition cost).	
glucose control	0	0.6015	4	Last updated May 2017 on a case-by-case basis, with particular consideration for people who are older or frail, for adults with type 2 diabetes: who are unlikely to achieve longer-term risk-reduction benefits, for example, people with a reduced life expectancy for whom tight blood glucose control poses a high risk of the consequences of hypoglycaemia, for example, people who are at risk of falling, people who have impaired awareness of hypoglycaemia, and people who drive or operate machinery as part of their job for whom intensive management would not be appropriate, for example, people with significant comorbidities.	If an adult with type 2 diabetes is symptomatically hyperglycaemic, consider insulin (see recommendations – ) or a sulfonylurea, and review treatment when blood glucose control has been achieved.	Last updated May 2017 on a case-by-case basis, with particular consideration for people who are older or frail, for adults with type 2 diabetes: who are unlikely to achieve longer-term risk-reduction benefits, for example, people with a reduced life expectancy for whom tight blood glucose control poses a high risk of the consequences of hypoglycaemia, for example, people who are at risk of falling, people who have impaired awareness of hypoglycaemia, and people who drive or operate machinery as part of their job for whom intensive management would not be appropriate, for example, people with significant comorbidities.	If an adult with type 2 diabetes is symptomatically hyperglycaemic, consider insulin (see recommendations – ) or a sulfonylurea, and review treatment when blood glucose control has been achieved.	
myocardial infarction	1	0.5894	2	For guidance on the primary and secondary prevention of cardiovascular disease in adults with type 2 diabetes, see the NICE guidelines on cardiovascular disease and myocardial infarction.	For guidance on the primary and secondary prevention of cardiovascular disease in adults with type 2 diabetes, see the NICE guidelines on cardiovascular disease and myocardial infarction.	
secondary prevention	0	0.5894	2	For guidance on the primary and secondary prevention of cardiovascular disease in adults with type 2 diabetes, see the NICE guidelines on cardiovascular disease and myocardial infarction.	For guidance on the primary and secondary prevention of cardiovascular disease in adults with type 2 diabetes, see the NICE guidelines on cardiovascular disease and myocardial infarction.	
glucose levels	0	0.5674	8	Take the Driver and Vehicle Licensing Agency (DVLA) At a glance guide to the current medical standards of fitness to drive into account when offering self-monitoring of blood glucose levels for adults with type 2 diabetes.	Do not routinely offer self-monitoring of blood glucose levels for adults with type 2 diabetes unless: the person is on insulin or there is evidence of hypoglycaemic episodes or the person is on oral medication that may increase their risk of hypoglycaemia while driving or operating machinery or	Consider short-term self-monitoring of blood glucose levels in adults with type 2 diabetes (and review treatment as necessary): when starting treatment with oral or intravenous corticosteroids or to confirm suspected hypoglycaemia.	If adults with type 2 diabetes are self-monitoring their blood glucose levels, carry out a structured assessment at least annually	Take the Driver and Vehicle Licensing Agency (DVLA) At a glance guide to the current medical standards of fitness to drive into account when offering self-monitoring of blood glucose levels for adults with type 2 diabetes.	Do not routinely offer self-monitoring of blood glucose levels for adults with type 2 diabetes unless: the person is on insulin or there is evidence of hypoglycaemic episodes or the person is on oral medication that may increase their risk of hypoglycaemia while driving or operating machinery or	Consider short-term self-monitoring of blood glucose levels in adults with type 2 diabetes (and review treatment as necessary): when starting treatment with oral or intravenous corticosteroids or to confirm suspected hypoglycaemia.	If adults with type 2 diabetes are self-monitoring their blood glucose levels, carry out a structured assessment at least annually	
initial drug	0	0.5583	8	Offer standard-release metformin as the initial drug treatment for adults with type 2 diabetes.	In adults with type 2 diabetes, if metformin is contraindicated or not tolerated, consider initial drug treatment with: a dipeptidyl peptidase-4 (DPP-4) inhibitor or pioglitazone or a sulfonylurea.	In adults with type 2 diabetes, if initial drug treatment with metformin has not continued to control HbA1c to below the person's individually agreed threshold for intensification, consider dual therapy with: metformin and a DPP-4 inhibitor or metformin and pioglitazone or metformin and a sulfonylurea.	In adults with type 2 diabetes, if metformin is contraindicated or not tolerated and initial drug treatment has not continued to control HbA1c to below the person's individually agreed threshold for intensification, consider dual therapy with: a DPP-4 inhibitor and pioglitazone or a DPP-4 inhibitor and a sulfonylurea or pioglitazone and a sulfonylurea.	Offer standard-release metformin as the initial drug treatment for adults with type 2 diabetes.	In adults with type 2 diabetes, if metformin is contraindicated or not tolerated, consider initial drug treatment with: a dipeptidyl peptidase-4 (DPP-4) inhibitor or pioglitazone or a sulfonylurea.	In adults with type 2 diabetes, if initial drug treatment with metformin has not continued to control HbA1c to below the person's individually agreed threshold for intensification, consider dual therapy with: metformin and a DPP-4 inhibitor or metformin and pioglitazone or metformin and a sulfonylurea.	In adults with type 2 diabetes, if metformin is contraindicated or not tolerated and initial drug treatment has not continued to control HbA1c to below the person's individually agreed threshold for intensification, consider dual therapy with: a DPP-4 inhibitor and pioglitazone or a DPP-4 inhibitor and a sulfonylurea or pioglitazone and a sulfonylurea.	
dual therapy	0	0.5419	8	In adults with type 2 diabetes, if initial drug treatment with metformin has not continued to control HbA1c to below the person's individually agreed threshold for intensification, consider dual therapy with: metformin and a DPP-4 inhibitor or metformin and pioglitazone or metformin and a sulfonylurea.	In adults with type 2 diabetes, if metformin is contraindicated or not tolerated and initial drug treatment has not continued to control HbA1c to below the person's individually agreed threshold for intensification, consider dual therapy with: a DPP-4 inhibitor and pioglitazone or a DPP-4 inhibitor and a sulfonylurea or pioglitazone and a sulfonylurea.	In adults with type 2 diabetes, if dual therapy with metformin and another oral drug (see recommendation ) has not continued to control HbA1c to below the person's individually agreed threshold for intensification, consider either: triple therapy with: metformin, a DPP-4 inhibitor and a sulfonylurea or metformin, pioglitazone and a sulfonylurea or starting insulin-based treatment (see recommendations – ).	In adults with type 2 diabetes, if metformin is contraindicated or not tolerated, and if dual therapy with 2 oral drugs (see recommendation ) has not continued to control HbA1c to below the person's individually agreed threshold for intensification, consider insulin-based treatment (see recommendations – ).	In adults with type 2 diabetes, if initial drug treatment with metformin has not continued to control HbA1c to below the person's individually agreed threshold for intensification, consider dual therapy with: metformin and a DPP-4 inhibitor or metformin and pioglitazone or metformin and a sulfonylurea.	In adults with type 2 diabetes, if metformin is contraindicated or not tolerated and initial drug treatment has not continued to control HbA1c to below the person's individually agreed threshold for intensification, consider dual therapy with: a DPP-4 inhibitor and pioglitazone or a DPP-4 inhibitor and a sulfonylurea or pioglitazone and a sulfonylurea.	In adults with type 2 diabetes, if dual therapy with metformin and another oral drug (see recommendation ) has not continued to control HbA1c to below the person's individually agreed threshold for intensification, consider either: triple therapy with: metformin, a DPP-4 inhibitor and a sulfonylurea or metformin, pioglitazone and a sulfonylurea or starting insulin-based treatment (see recommendations – ).	In adults with type 2 diabetes, if metformin is contraindicated or not tolerated, and if dual therapy with 2 oral drugs (see recommendation ) has not continued to control HbA1c to below the person's individually agreed threshold for intensification, consider insulin-based treatment (see recommendations – ).	
weight loss	0	0.53	6	For adults with type 2 diabetes who are overweight, set an initial body weight loss target of 5–10percent	Be aware that there are other possible reasons for a low HbA1c level, for example, deteriorating renal function or sudden weight loss.	If triple therapy with metformin and 2 other oral drugs (see recommendation ) is not effective, not tolerated or contraindicated, consider combination therapy with metformin, a sulfonylurea and a glucagon-like peptide-1 (GLP-1) mimetic for adults with type 2 diabetes who: have a BMI of 35 kg m2 or higher (adjust accordingly for people from black, Asian and other minority ethnic groups) and specific psychological or other medical problems associated with obesity or have a BMI lower than 35 kg m2and: for whom insulin therapy would have significant occupational implications or weight loss would benefit other significant obesity-related comorbidities.	For adults with type 2 diabetes who are overweight, set an initial body weight loss target of 5–10percent	Be aware that there are other possible reasons for a low HbA1c level, for example, deteriorating renal function or sudden weight loss.	If triple therapy with metformin and 2 other oral drugs (see recommendation ) is not effective, not tolerated or contraindicated, consider combination therapy with metformin, a sulfonylurea and a glucagon-like peptide-1 (GLP-1) mimetic for adults with type 2 diabetes who: have a BMI of 35 kg m2 or higher (adjust accordingly for people from black, Asian and other minority ethnic groups) and specific psychological or other medical problems associated with obesity or have a BMI lower than 35 kg m2and: for whom insulin therapy would have significant occupational implications or weight loss would benefit other significant obesity-related comorbidities.	
triple therapy	0	0.5207	4	In adults with type 2 diabetes, if dual therapy with metformin and another oral drug (see recommendation ) has not continued to control HbA1c to below the person's individually agreed threshold for intensification, consider either: triple therapy with: metformin, a DPP-4 inhibitor and a sulfonylurea or metformin, pioglitazone and a sulfonylurea or starting insulin-based treatment (see recommendations – ).	If triple therapy with metformin and 2 other oral drugs (see recommendation ) is not effective, not tolerated or contraindicated, consider combination therapy with metformin, a sulfonylurea and a glucagon-like peptide-1 (GLP-1) mimetic for adults with type 2 diabetes who: have a BMI of 35 kg m2 or higher (adjust accordingly for people from black, Asian and other minority ethnic groups) and specific psychological or other medical problems associated with obesity or have a BMI lower than 35 kg m2and: for whom insulin therapy would have significant occupational implications or weight loss would benefit other significant obesity-related comorbidities.	In adults with type 2 diabetes, if dual therapy with metformin and another oral drug (see recommendation ) has not continued to control HbA1c to below the person's individually agreed threshold for intensification, consider either: triple therapy with: metformin, a DPP-4 inhibitor and a sulfonylurea or metformin, pioglitazone and a sulfonylurea or starting insulin-based treatment (see recommendations – ).	If triple therapy with metformin and 2 other oral drugs (see recommendation ) is not effective, not tolerated or contraindicated, consider combination therapy with metformin, a sulfonylurea and a glucagon-like peptide-1 (GLP-1) mimetic for adults with type 2 diabetes who: have a BMI of 35 kg m2 or higher (adjust accordingly for people from black, Asian and other minority ethnic groups) and specific psychological or other medical problems associated with obesity or have a BMI lower than 35 kg m2and: for whom insulin therapy would have significant occupational implications or weight loss would benefit other significant obesity-related comorbidities.	
nice guideline	0	0.5078	12	For recommendations on lifestyle advice, see the NICE guidelines on: preventing excess weight gain, weight management, obesity, physical activity, smoking: brief interventions and referrals, stop smoking services, smoking: harm reduction, and smoking: acute, maternity and mental health services.	For recommendations on bariatric surgery for people with recent-onset type 2 diabetes, see the section on bariatric surgery for people with recent-onset type 2 diabetes in the NICE guideline on obesity.	Provide lifestyle advice (see section in this guideline and the lifestyle interventions section in hypertension in adults NICE guideline CG127) if blood	For guidance on the primary and secondary prevention of cardiovascular disease in adults with type 2 diabetes, see the NICE guidelines on cardiovascular disease and myocardial infarction.	For guidance on HbA1c targets for women with type 2 diabetes who are pregnant or planning to become pregnant, see the NICE guideline on diabetes in pregnancy.	For more information, see the NICE guideline on diabetes in pregnancy.	For recommendations on lifestyle advice, see the NICE guidelines on: preventing excess weight gain, weight management, obesity, physical activity, smoking: brief interventions and referrals, stop smoking services, smoking: harm reduction, and smoking: acute, maternity and mental health services.	For recommendations on bariatric surgery for people with recent-onset type 2 diabetes, see the section on bariatric surgery for people with recent-onset type 2 diabetes in the NICE guideline on obesity.	Provide lifestyle advice (see section in this guideline and the lifestyle interventions section in hypertension in adults NICE guideline CG127) if blood	For guidance on the primary and secondary prevention of cardiovascular disease in adults with type 2 diabetes, see the NICE guidelines on cardiovascular disease and myocardial infarction.	For guidance on HbA1c targets for women with type 2 diabetes who are pregnant or planning to become pregnant, see the NICE guideline on diabetes in pregnancy.	For more information, see the NICE guideline on diabetes in pregnancy.	
3–6-monthly intervals	0	0.5	2	In adults with type 2 diabetes, measure HbA1c levels at: 3–6-monthly intervals (tailored to individual needs), until the HbA1c is stable on unchanging therapy 6-monthly intervals once the HbA1c level and blood glucose lowering therapy are stable.	In adults with type 2 diabetes, measure HbA1c levels at: 3–6-monthly intervals (tailored to individual needs), until the HbA1c is stable on unchanging therapy 6-monthly intervals once the HbA1c level and blood glucose lowering therapy are stable.	
6-monthly intervals	0	0.5	2	In adults with type 2 diabetes, measure HbA1c levels at: 3–6-monthly intervals (tailored to individual needs), until the HbA1c is stable on unchanging therapy 6-monthly intervals once the HbA1c level and blood glucose lowering therapy are stable.	In adults with type 2 diabetes, measure HbA1c levels at: 3–6-monthly intervals (tailored to individual needs), until the HbA1c is stable on unchanging therapy 6-monthly intervals once the HbA1c level and blood glucose lowering therapy are stable.	
acquisition cost	0	0.5	2	Last updated May 2017 safety (see Medicines and Healthcare products Regulatory Agency MHRA guidance) and tolerability of the drug treatment(s) the person's individual clinical circumstances, for example, comorbidities, risks from polypharmacy the person's individual preferences and needs the licensed indications or combinations available cost (if 2 drugs in the same class are appropriate, choose the option with the lowest acquisition cost).	Last updated May 2017 safety (see Medicines and Healthcare products Regulatory Agency MHRA guidance) and tolerability of the drug treatment(s) the person's individual clinical circumstances, for example, comorbidities, risks from polypharmacy the person's individual preferences and needs the licensed indications or combinations available cost (if 2 drugs in the same class are appropriate, choose the option with the lowest acquisition cost).	
acute intercurrent	0	0.5	2	Be aware that adults with type 2 diabetes who have acute intercurrent illness are at risk of worsening hyperglycaemia	Be aware that adults with type 2 diabetes who have acute intercurrent illness are at risk of worsening hyperglycaemia	
agency mhra	0	0.5	2	Last updated May 2017 safety (see Medicines and Healthcare products Regulatory Agency MHRA guidance) and tolerability of the drug treatment(s) the person's individual clinical circumstances, for example, comorbidities, risks from polypharmacy the person's individual preferences and needs the licensed indications or combinations available cost (if 2 drugs in the same class are appropriate, choose the option with the lowest acquisition cost).	Last updated May 2017 safety (see Medicines and Healthcare products Regulatory Agency MHRA guidance) and tolerability of the drug treatment(s) the person's individual clinical circumstances, for example, comorbidities, risks from polypharmacy the person's individual preferences and needs the licensed indications or combinations available cost (if 2 drugs in the same class are appropriate, choose the option with the lowest acquisition cost).	
annual reinforcement	0	0.5	2	Last updated May 2017 annual reinforcement and review	Last updated May 2017 annual reinforcement and review	
care pathway	0	0.5	2	Ensure that all members of the diabetes healthcare team are familiar with the patient-education programmes available locally, that these programmes are integrated with the rest of the care pathway, and that adults with type 2 diabetes and their family members or carers (as appropriate) have the opportunity to contribute to the design and provision of local programmes.	Ensure that all members of the diabetes healthcare team are familiar with the patient-education programmes available locally, that these programmes are integrated with the rest of the care pathway, and that adults with type 2 diabetes and their family members or carers (as appropriate) have the opportunity to contribute to the design and provision of local programmes.	
clinical circumstances	0	0.5	2	Last updated May 2017 safety (see Medicines and Healthcare products Regulatory Agency MHRA guidance) and tolerability of the drug treatment(s) the person's individual clinical circumstances, for example, comorbidities, risks from polypharmacy the person's individual preferences and needs the licensed indications or combinations available cost (if 2 drugs in the same class are appropriate, choose the option with the lowest acquisition cost).	Last updated May 2017 safety (see Medicines and Healthcare products Regulatory Agency MHRA guidance) and tolerability of the drug treatment(s) the person's individual clinical circumstances, for example, comorbidities, risks from polypharmacy the person's individual preferences and needs the licensed indications or combinations available cost (if 2 drugs in the same class are appropriate, choose the option with the lowest acquisition cost).	
combination therapy	0	0.5	2	If triple therapy with metformin and 2 other oral drugs (see recommendation ) is not effective, not tolerated or contraindicated, consider combination therapy with metformin, a sulfonylurea and a glucagon-like peptide-1 (GLP-1) mimetic for adults with type 2 diabetes who: have a BMI of 35 kg m2 or higher (adjust accordingly for people from black, Asian and other minority ethnic groups) and specific psychological or other medical problems associated with obesity or have a BMI lower than 35 kg m2and: for whom insulin therapy would have significant occupational implications or weight loss would benefit other significant obesity-related comorbidities.	If triple therapy with metformin and 2 other oral drugs (see recommendation ) is not effective, not tolerated or contraindicated, consider combination therapy with metformin, a sulfonylurea and a glucagon-like peptide-1 (GLP-1) mimetic for adults with type 2 diabetes who: have a BMI of 35 kg m2 or higher (adjust accordingly for people from black, Asian and other minority ethnic groups) and specific psychological or other medical problems associated with obesity or have a BMI lower than 35 kg m2and: for whom insulin therapy would have significant occupational implications or weight loss would benefit other significant obesity-related comorbidities.	
continued benefit	0	0.5	2	The assessment should include: the person's self-monitoring skills the quality and frequency of testing checking that the person knows how to interpret the blood glucose results and what action to take the impact on the person's quality of life the continued benefit to the person the equipment used.	The assessment should include: the person's self-monitoring skills the quality and frequency of testing checking that the person knows how to interpret the blood glucose results and what action to take the impact on the person's quality of life the continued benefit to the person the equipment used.	
diabetes healthcare	0	0.5	2	Ensure that all members of the diabetes healthcare team are familiar with the patient-education programmes available locally, that these programmes are integrated with the rest of the care pathway, and that adults with type 2 diabetes and their family members or carers (as appropriate) have the opportunity to contribute to the design and provision of local programmes.	Ensure that all members of the diabetes healthcare team are familiar with the patient-education programmes available locally, that these programmes are integrated with the rest of the care pathway, and that adults with type 2 diabetes and their family members or carers (as appropriate) have the opportunity to contribute to the design and provision of local programmes.	
drug treatment(s)	0	0.5	2	Last updated May 2017 safety (see Medicines and Healthcare products Regulatory Agency MHRA guidance) and tolerability of the drug treatment(s) the person's individual clinical circumstances, for example, comorbidities, risks from polypharmacy the person's individual preferences and needs the licensed indications or combinations available cost (if 2 drugs in the same class are appropriate, choose the option with the lowest acquisition cost).	Last updated May 2017 safety (see Medicines and Healthcare products Regulatory Agency MHRA guidance) and tolerability of the drug treatment(s) the person's individual clinical circumstances, for example, comorbidities, risks from polypharmacy the person's individual preferences and needs the licensed indications or combinations available cost (if 2 drugs in the same class are appropriate, choose the option with the lowest acquisition cost).	
education programme	1	0.5	6	Ensure that any structured education programme for adults with type 2 diabetes includes the following components:	Ensure the patient-education programme provides the necessary resources to support the educators, and that educators are properly trained and given time to develop and maintain their skills.	Ensure that all members of the diabetes healthcare team are familiar with the patient-education programmes available locally, that these programmes are integrated with the rest of the care pathway, and that adults with type 2 diabetes and their family members or carers (as appropriate) have the opportunity to contribute to the design and provision of local programmes.	Ensure that any structured education programme for adults with type 2 diabetes includes the following components:	Ensure the patient-education programme provides the necessary resources to support the educators, and that educators are properly trained and given time to develop and maintain their skills.	Ensure that all members of the diabetes healthcare team are familiar with the patient-education programmes available locally, that these programmes are integrated with the rest of the care pathway, and that adults with type 2 diabetes and their family members or carers (as appropriate) have the opportunity to contribute to the design and provision of local programmes.	
ethnic groups	0	0.5	2	If triple therapy with metformin and 2 other oral drugs (see recommendation ) is not effective, not tolerated or contraindicated, consider combination therapy with metformin, a sulfonylurea and a glucagon-like peptide-1 (GLP-1) mimetic for adults with type 2 diabetes who: have a BMI of 35 kg m2 or higher (adjust accordingly for people from black, Asian and other minority ethnic groups) and specific psychological or other medical problems associated with obesity or have a BMI lower than 35 kg m2and: for whom insulin therapy would have significant occupational implications or weight loss would benefit other significant obesity-related comorbidities.	If triple therapy with metformin and 2 other oral drugs (see recommendation ) is not effective, not tolerated or contraindicated, consider combination therapy with metformin, a sulfonylurea and a glucagon-like peptide-1 (GLP-1) mimetic for adults with type 2 diabetes who: have a BMI of 35 kg m2 or higher (adjust accordingly for people from black, Asian and other minority ethnic groups) and specific psychological or other medical problems associated with obesity or have a BMI lower than 35 kg m2and: for whom insulin therapy would have significant occupational implications or weight loss would benefit other significant obesity-related comorbidities.	
failure type	0	0.5	0	
glucagon-like peptide-1	1	0.5	2	If triple therapy with metformin and 2 other oral drugs (see recommendation ) is not effective, not tolerated or contraindicated, consider combination therapy with metformin, a sulfonylurea and a glucagon-like peptide-1 (GLP-1) mimetic for adults with type 2 diabetes who: have a BMI of 35 kg m2 or higher (adjust accordingly for people from black, Asian and other minority ethnic groups) and specific psychological or other medical problems associated with obesity or have a BMI lower than 35 kg m2and: for whom insulin therapy would have significant occupational implications or weight loss would benefit other significant obesity-related comorbidities.	If triple therapy with metformin and 2 other oral drugs (see recommendation ) is not effective, not tolerated or contraindicated, consider combination therapy with metformin, a sulfonylurea and a glucagon-like peptide-1 (GLP-1) mimetic for adults with type 2 diabetes who: have a BMI of 35 kg m2 or higher (adjust accordingly for people from black, Asian and other minority ethnic groups) and specific psychological or other medical problems associated with obesity or have a BMI lower than 35 kg m2and: for whom insulin therapy would have significant occupational implications or weight loss would benefit other significant obesity-related comorbidities.	
glucose results	0	0.5	2	The assessment should include: the person's self-monitoring skills the quality and frequency of testing checking that the person knows how to interpret the blood glucose results and what action to take the impact on the person's quality of life the continued benefit to the person the equipment used.	The assessment should include: the person's self-monitoring skills the quality and frequency of testing checking that the person knows how to interpret the blood glucose results and what action to take the impact on the person's quality of life the continued benefit to the person the equipment used.	
hba1c measurement	0	0.5	2	HbA1c measurement and targets	HbA1c measurement and targets	
healthcare team	0	0.5	2	Ensure that all members of the diabetes healthcare team are familiar with the patient-education programmes available locally, that these programmes are integrated with the rest of the care pathway, and that adults with type 2 diabetes and their family members or carers (as appropriate) have the opportunity to contribute to the design and provision of local programmes.	Ensure that all members of the diabetes healthcare team are familiar with the patient-education programmes available locally, that these programmes are integrated with the rest of the care pathway, and that adults with type 2 diabetes and their family members or carers (as appropriate) have the opportunity to contribute to the design and provision of local programmes.	
individual clinical	0	0.5	2	Last updated May 2017 safety (see Medicines and Healthcare products Regulatory Agency MHRA guidance) and tolerability of the drug treatment(s) the person's individual clinical circumstances, for example, comorbidities, risks from polypharmacy the person's individual preferences and needs the licensed indications or combinations available cost (if 2 drugs in the same class are appropriate, choose the option with the lowest acquisition cost).	Last updated May 2017 safety (see Medicines and Healthcare products Regulatory Agency MHRA guidance) and tolerability of the drug treatment(s) the person's individual clinical circumstances, for example, comorbidities, risks from polypharmacy the person's individual preferences and needs the licensed indications or combinations available cost (if 2 drugs in the same class are appropriate, choose the option with the lowest acquisition cost).	
individual preferences	0	0.5	2	Last updated May 2017 safety (see Medicines and Healthcare products Regulatory Agency MHRA guidance) and tolerability of the drug treatment(s) the person's individual clinical circumstances, for example, comorbidities, risks from polypharmacy the person's individual preferences and needs the licensed indications or combinations available cost (if 2 drugs in the same class are appropriate, choose the option with the lowest acquisition cost).	Last updated May 2017 safety (see Medicines and Healthcare products Regulatory Agency MHRA guidance) and tolerability of the drug treatment(s) the person's individual clinical circumstances, for example, comorbidities, risks from polypharmacy the person's individual preferences and needs the licensed indications or combinations available cost (if 2 drugs in the same class are appropriate, choose the option with the lowest acquisition cost).	
intercurrent illness	0	0.5	2	Be aware that adults with type 2 diabetes who have acute intercurrent illness are at risk of worsening hyperglycaemia	Be aware that adults with type 2 diabetes who have acute intercurrent illness are at risk of worsening hyperglycaemia	
kg m2	0	0.5	2	If triple therapy with metformin and 2 other oral drugs (see recommendation ) is not effective, not tolerated or contraindicated, consider combination therapy with metformin, a sulfonylurea and a glucagon-like peptide-1 (GLP-1) mimetic for adults with type 2 diabetes who: have a BMI of 35 kg m2 or higher (adjust accordingly for people from black, Asian and other minority ethnic groups) and specific psychological or other medical problems associated with obesity or have a BMI lower than 35 kg m2and: for whom insulin therapy would have significant occupational implications or weight loss would benefit other significant obesity-related comorbidities.	If triple therapy with metformin and 2 other oral drugs (see recommendation ) is not effective, not tolerated or contraindicated, consider combination therapy with metformin, a sulfonylurea and a glucagon-like peptide-1 (GLP-1) mimetic for adults with type 2 diabetes who: have a BMI of 35 kg m2 or higher (adjust accordingly for people from black, Asian and other minority ethnic groups) and specific psychological or other medical problems associated with obesity or have a BMI lower than 35 kg m2and: for whom insulin therapy would have significant occupational implications or weight loss would benefit other significant obesity-related comorbidities.	
kg m2and	0	0.5	2	If triple therapy with metformin and 2 other oral drugs (see recommendation ) is not effective, not tolerated or contraindicated, consider combination therapy with metformin, a sulfonylurea and a glucagon-like peptide-1 (GLP-1) mimetic for adults with type 2 diabetes who: have a BMI of 35 kg m2 or higher (adjust accordingly for people from black, Asian and other minority ethnic groups) and specific psychological or other medical problems associated with obesity or have a BMI lower than 35 kg m2and: for whom insulin therapy would have significant occupational implications or weight loss would benefit other significant obesity-related comorbidities.	If triple therapy with metformin and 2 other oral drugs (see recommendation ) is not effective, not tolerated or contraindicated, consider combination therapy with metformin, a sulfonylurea and a glucagon-like peptide-1 (GLP-1) mimetic for adults with type 2 diabetes who: have a BMI of 35 kg m2 or higher (adjust accordingly for people from black, Asian and other minority ethnic groups) and specific psychological or other medical problems associated with obesity or have a BMI lower than 35 kg m2and: for whom insulin therapy would have significant occupational implications or weight loss would benefit other significant obesity-related comorbidities.	
licensed indications	0	0.5	2	Last updated May 2017 safety (see Medicines and Healthcare products Regulatory Agency MHRA guidance) and tolerability of the drug treatment(s) the person's individual clinical circumstances, for example, comorbidities, risks from polypharmacy the person's individual preferences and needs the licensed indications or combinations available cost (if 2 drugs in the same class are appropriate, choose the option with the lowest acquisition cost).	Last updated May 2017 safety (see Medicines and Healthcare products Regulatory Agency MHRA guidance) and tolerability of the drug treatment(s) the person's individual clinical circumstances, for example, comorbidities, risks from polypharmacy the person's individual preferences and needs the licensed indications or combinations available cost (if 2 drugs in the same class are appropriate, choose the option with the lowest acquisition cost).	
local programmes	0	0.5	2	Ensure that all members of the diabetes healthcare team are familiar with the patient-education programmes available locally, that these programmes are integrated with the rest of the care pathway, and that adults with type 2 diabetes and their family members or carers (as appropriate) have the opportunity to contribute to the design and provision of local programmes.	Ensure that all members of the diabetes healthcare team are familiar with the patient-education programmes available locally, that these programmes are integrated with the rest of the care pathway, and that adults with type 2 diabetes and their family members or carers (as appropriate) have the opportunity to contribute to the design and provision of local programmes.	
measure hba1c	0	0.5	4	In adults with type 2 diabetes, measure HbA1c levels at: 3–6-monthly intervals (tailored to individual needs), until the HbA1c is stable on unchanging therapy 6-monthly intervals once the HbA1c level and blood glucose lowering therapy are stable.	Use methods to measure HbA1c that have been calibrated according to	In adults with type 2 diabetes, measure HbA1c levels at: 3–6-monthly intervals (tailored to individual needs), until the HbA1c is stable on unchanging therapy 6-monthly intervals once the HbA1c level and blood glucose lowering therapy are stable.	Use methods to measure HbA1c that have been calibrated according to	
medical problems	0	0.5	2	If triple therapy with metformin and 2 other oral drugs (see recommendation ) is not effective, not tolerated or contraindicated, consider combination therapy with metformin, a sulfonylurea and a glucagon-like peptide-1 (GLP-1) mimetic for adults with type 2 diabetes who: have a BMI of 35 kg m2 or higher (adjust accordingly for people from black, Asian and other minority ethnic groups) and specific psychological or other medical problems associated with obesity or have a BMI lower than 35 kg m2and: for whom insulin therapy would have significant occupational implications or weight loss would benefit other significant obesity-related comorbidities.	If triple therapy with metformin and 2 other oral drugs (see recommendation ) is not effective, not tolerated or contraindicated, consider combination therapy with metformin, a sulfonylurea and a glucagon-like peptide-1 (GLP-1) mimetic for adults with type 2 diabetes who: have a BMI of 35 kg m2 or higher (adjust accordingly for people from black, Asian and other minority ethnic groups) and specific psychological or other medical problems associated with obesity or have a BMI lower than 35 kg m2and: for whom insulin therapy would have significant occupational implications or weight loss would benefit other significant obesity-related comorbidities.	
mhra guidance	0	0.5	2	Last updated May 2017 safety (see Medicines and Healthcare products Regulatory Agency MHRA guidance) and tolerability of the drug treatment(s) the person's individual clinical circumstances, for example, comorbidities, risks from polypharmacy the person's individual preferences and needs the licensed indications or combinations available cost (if 2 drugs in the same class are appropriate, choose the option with the lowest acquisition cost).	Last updated May 2017 safety (see Medicines and Healthcare products Regulatory Agency MHRA guidance) and tolerability of the drug treatment(s) the person's individual clinical circumstances, for example, comorbidities, risks from polypharmacy the person's individual preferences and needs the licensed indications or combinations available cost (if 2 drugs in the same class are appropriate, choose the option with the lowest acquisition cost).	
minority ethnic	0	0.5	2	If triple therapy with metformin and 2 other oral drugs (see recommendation ) is not effective, not tolerated or contraindicated, consider combination therapy with metformin, a sulfonylurea and a glucagon-like peptide-1 (GLP-1) mimetic for adults with type 2 diabetes who: have a BMI of 35 kg m2 or higher (adjust accordingly for people from black, Asian and other minority ethnic groups) and specific psychological or other medical problems associated with obesity or have a BMI lower than 35 kg m2and: for whom insulin therapy would have significant occupational implications or weight loss would benefit other significant obesity-related comorbidities.	If triple therapy with metformin and 2 other oral drugs (see recommendation ) is not effective, not tolerated or contraindicated, consider combination therapy with metformin, a sulfonylurea and a glucagon-like peptide-1 (GLP-1) mimetic for adults with type 2 diabetes who: have a BMI of 35 kg m2 or higher (adjust accordingly for people from black, Asian and other minority ethnic groups) and specific psychological or other medical problems associated with obesity or have a BMI lower than 35 kg m2and: for whom insulin therapy would have significant occupational implications or weight loss would benefit other significant obesity-related comorbidities.	
obesity-related comorbidities	0	0.5	2	If triple therapy with metformin and 2 other oral drugs (see recommendation ) is not effective, not tolerated or contraindicated, consider combination therapy with metformin, a sulfonylurea and a glucagon-like peptide-1 (GLP-1) mimetic for adults with type 2 diabetes who: have a BMI of 35 kg m2 or higher (adjust accordingly for people from black, Asian and other minority ethnic groups) and specific psychological or other medical problems associated with obesity or have a BMI lower than 35 kg m2and: for whom insulin therapy would have significant occupational implications or weight loss would benefit other significant obesity-related comorbidities.	If triple therapy with metformin and 2 other oral drugs (see recommendation ) is not effective, not tolerated or contraindicated, consider combination therapy with metformin, a sulfonylurea and a glucagon-like peptide-1 (GLP-1) mimetic for adults with type 2 diabetes who: have a BMI of 35 kg m2 or higher (adjust accordingly for people from black, Asian and other minority ethnic groups) and specific psychological or other medical problems associated with obesity or have a BMI lower than 35 kg m2and: for whom insulin therapy would have significant occupational implications or weight loss would benefit other significant obesity-related comorbidities.	
occupational implications	0	0.5	2	If triple therapy with metformin and 2 other oral drugs (see recommendation ) is not effective, not tolerated or contraindicated, consider combination therapy with metformin, a sulfonylurea and a glucagon-like peptide-1 (GLP-1) mimetic for adults with type 2 diabetes who: have a BMI of 35 kg m2 or higher (adjust accordingly for people from black, Asian and other minority ethnic groups) and specific psychological or other medical problems associated with obesity or have a BMI lower than 35 kg m2and: for whom insulin therapy would have significant occupational implications or weight loss would benefit other significant obesity-related comorbidities.	If triple therapy with metformin and 2 other oral drugs (see recommendation ) is not effective, not tolerated or contraindicated, consider combination therapy with metformin, a sulfonylurea and a glucagon-like peptide-1 (GLP-1) mimetic for adults with type 2 diabetes who: have a BMI of 35 kg m2 or higher (adjust accordingly for people from black, Asian and other minority ethnic groups) and specific psychological or other medical problems associated with obesity or have a BMI lower than 35 kg m2and: for whom insulin therapy would have significant occupational implications or weight loss would benefit other significant obesity-related comorbidities.	
patient-education programme	0	0.5	4	Ensure the patient-education programme provides the necessary resources to support the educators, and that educators are properly trained and given time to develop and maintain their skills.	Ensure that all members of the diabetes healthcare team are familiar with the patient-education programmes available locally, that these programmes are integrated with the rest of the care pathway, and that adults with type 2 diabetes and their family members or carers (as appropriate) have the opportunity to contribute to the design and provision of local programmes.	Ensure the patient-education programme provides the necessary resources to support the educators, and that educators are properly trained and given time to develop and maintain their skills.	Ensure that all members of the diabetes healthcare team are familiar with the patient-education programmes available locally, that these programmes are integrated with the rest of the care pathway, and that adults with type 2 diabetes and their family members or carers (as appropriate) have the opportunity to contribute to the design and provision of local programmes.	
review ensure	0	0.5	0	
self-manage diabetes	0	0.5	2	It has specific aims and learning objectives, and supports the person and their family members and carers in developing attitudes, beliefs, knowledge and skills to self-manage diabetes.	It has specific aims and learning objectives, and supports the person and their family members and carers in developing attitudes, beliefs, knowledge and skills to self-manage diabetes.	
self-monitoring skills	0	0.5	2	The assessment should include: the person's self-monitoring skills the quality and frequency of testing checking that the person knows how to interpret the blood glucose results and what action to take the impact on the person's quality of life the continued benefit to the person the equipment used.	The assessment should include: the person's self-monitoring skills the quality and frequency of testing checking that the person knows how to interpret the blood glucose results and what action to take the impact on the person's quality of life the continued benefit to the person the equipment used.	
significant obesity-related	0	0.5	2	If triple therapy with metformin and 2 other oral drugs (see recommendation ) is not effective, not tolerated or contraindicated, consider combination therapy with metformin, a sulfonylurea and a glucagon-like peptide-1 (GLP-1) mimetic for adults with type 2 diabetes who: have a BMI of 35 kg m2 or higher (adjust accordingly for people from black, Asian and other minority ethnic groups) and specific psychological or other medical problems associated with obesity or have a BMI lower than 35 kg m2and: for whom insulin therapy would have significant occupational implications or weight loss would benefit other significant obesity-related comorbidities.	If triple therapy with metformin and 2 other oral drugs (see recommendation ) is not effective, not tolerated or contraindicated, consider combination therapy with metformin, a sulfonylurea and a glucagon-like peptide-1 (GLP-1) mimetic for adults with type 2 diabetes who: have a BMI of 35 kg m2 or higher (adjust accordingly for people from black, Asian and other minority ethnic groups) and specific psychological or other medical problems associated with obesity or have a BMI lower than 35 kg m2and: for whom insulin therapy would have significant occupational implications or weight loss would benefit other significant obesity-related comorbidities.	
significant occupational	0	0.5	2	If triple therapy with metformin and 2 other oral drugs (see recommendation ) is not effective, not tolerated or contraindicated, consider combination therapy with metformin, a sulfonylurea and a glucagon-like peptide-1 (GLP-1) mimetic for adults with type 2 diabetes who: have a BMI of 35 kg m2 or higher (adjust accordingly for people from black, Asian and other minority ethnic groups) and specific psychological or other medical problems associated with obesity or have a BMI lower than 35 kg m2and: for whom insulin therapy would have significant occupational implications or weight loss would benefit other significant obesity-related comorbidities.	If triple therapy with metformin and 2 other oral drugs (see recommendation ) is not effective, not tolerated or contraindicated, consider combination therapy with metformin, a sulfonylurea and a glucagon-like peptide-1 (GLP-1) mimetic for adults with type 2 diabetes who: have a BMI of 35 kg m2 or higher (adjust accordingly for people from black, Asian and other minority ethnic groups) and specific psychological or other medical problems associated with obesity or have a BMI lower than 35 kg m2and: for whom insulin therapy would have significant occupational implications or weight loss would benefit other significant obesity-related comorbidities.	
sodium–glucose cotransporter	0	0.5	2	Treatment with sodium–glucose cotransporter 2 (SGLT-2) inhibitors , may be appropriate for some adults with type 2 diabetes if metformin is contraindicated or not tolerated (see NICE's guidance on canagliflozin, dapagliflozin and empagliflozin as monotherapies for treating type 2 diabetes).	Treatment with sodium–glucose cotransporter 2 (SGLT-2) inhibitors , may be appropriate for some adults with type 2 diabetes if metformin is contraindicated or not tolerated (see NICE's guidance on canagliflozin, dapagliflozin and empagliflozin as monotherapies for treating type 2 diabetes).	
specific aims	0	0.5	2	It has specific aims and learning objectives, and supports the person and their family members and carers in developing attitudes, beliefs, knowledge and skills to self-manage diabetes.	It has specific aims and learning objectives, and supports the person and their family members and carers in developing attitudes, beliefs, knowledge and skills to self-manage diabetes.	
specific psychological	0	0.5	2	If triple therapy with metformin and 2 other oral drugs (see recommendation ) is not effective, not tolerated or contraindicated, consider combination therapy with metformin, a sulfonylurea and a glucagon-like peptide-1 (GLP-1) mimetic for adults with type 2 diabetes who: have a BMI of 35 kg m2 or higher (adjust accordingly for people from black, Asian and other minority ethnic groups) and specific psychological or other medical problems associated with obesity or have a BMI lower than 35 kg m2and: for whom insulin therapy would have significant occupational implications or weight loss would benefit other significant obesity-related comorbidities.	If triple therapy with metformin and 2 other oral drugs (see recommendation ) is not effective, not tolerated or contraindicated, consider combination therapy with metformin, a sulfonylurea and a glucagon-like peptide-1 (GLP-1) mimetic for adults with type 2 diabetes who: have a BMI of 35 kg m2 or higher (adjust accordingly for people from black, Asian and other minority ethnic groups) and specific psychological or other medical problems associated with obesity or have a BMI lower than 35 kg m2and: for whom insulin therapy would have significant occupational implications or weight loss would benefit other significant obesity-related comorbidities.	
structured assessment	0	0.5	2	If adults with type 2 diabetes are self-monitoring their blood glucose levels, carry out a structured assessment at least annually	If adults with type 2 diabetes are self-monitoring their blood glucose levels, carry out a structured assessment at least annually	
structured education	0	0.5	4	Offer structured education to adults with type 2 diabetes and or their family members or carers (as appropriate) at and around the time of diagnosis, with	Ensure that any structured education programme for adults with type 2 diabetes includes the following components:	Offer structured education to adults with type 2 diabetes and or their family members or carers (as appropriate) at and around the time of diagnosis, with	Ensure that any structured education programme for adults with type 2 diabetes includes the following components:	
therapy 6-monthly	0	0.5	2	In adults with type 2 diabetes, measure HbA1c levels at: 3–6-monthly intervals (tailored to individual needs), until the HbA1c is stable on unchanging therapy 6-monthly intervals once the HbA1c level and blood glucose lowering therapy are stable.	In adults with type 2 diabetes, measure HbA1c levels at: 3–6-monthly intervals (tailored to individual needs), until the HbA1c is stable on unchanging therapy 6-monthly intervals once the HbA1c level and blood glucose lowering therapy are stable.	
unchanging therapy	0	0.5	2	In adults with type 2 diabetes, measure HbA1c levels at: 3–6-monthly intervals (tailored to individual needs), until the HbA1c is stable on unchanging therapy 6-monthly intervals once the HbA1c level and blood glucose lowering therapy are stable.	In adults with type 2 diabetes, measure HbA1c levels at: 3–6-monthly intervals (tailored to individual needs), until the HbA1c is stable on unchanging therapy 6-monthly intervals once the HbA1c level and blood glucose lowering therapy are stable.	
hba1c level	0	0.4629	14	In adults with type 2 diabetes, measure HbA1c levels at: 3–6-monthly intervals (tailored to individual needs), until the HbA1c is stable on unchanging therapy 6-monthly intervals once the HbA1c level and blood glucose lowering therapy are stable.	For adults with type 2 diabetes managed either by lifestyle and diet, or by lifestyle and diet combined with a single drug not associated with hypoglycaemia, support the person to aim for an HbA1c level of 48 mmol mol ( percent)	For adults on a drug associated with hypoglycaemia, support the person to aim for an HbA1c level of 53 mmol mol ( percent).	In adults with type 2 diabetes, if HbA1c levels are not adequately controlled by a single drug and rise to 58 mmol mol ( percent) or higher: reinforce advice about diet, lifestyle and adherence to drug treatment and support the person to aim for an HbA1c level of 53 mmol mol ( percent) and intensify drug treatment.	Consider relaxing the target HbA1c level (see recommendations and )	If adults with type 2 diabetes achieve an HbA1c level that is lower than their target and they are not experiencing hypoglycaemia, encourage them to maintain it	Be aware that there are other possible reasons for a low HbA1c level, for example, deteriorating renal function or sudden weight loss.	In adults with type 2 diabetes, measure HbA1c levels at: 3–6-monthly intervals (tailored to individual needs), until the HbA1c is stable on unchanging therapy 6-monthly intervals once the HbA1c level and blood glucose lowering therapy are stable.	For adults with type 2 diabetes managed either by lifestyle and diet, or by lifestyle and diet combined with a single drug not associated with hypoglycaemia, support the person to aim for an HbA1c level of 48 mmol mol ( percent)	For adults on a drug associated with hypoglycaemia, support the person to aim for an HbA1c level of 53 mmol mol ( percent).	In adults with type 2 diabetes, if HbA1c levels are not adequately controlled by a single drug and rise to 58 mmol mol ( percent) or higher: reinforce advice about diet, lifestyle and adherence to drug treatment and support the person to aim for an HbA1c level of 53 mmol mol ( percent) and intensify drug treatment.	Consider relaxing the target HbA1c level (see recommendations and )	If adults with type 2 diabetes achieve an HbA1c level that is lower than their target and they are not experiencing hypoglycaemia, encourage them to maintain it	Be aware that there are other possible reasons for a low HbA1c level, for example, deteriorating renal function or sudden weight loss.	
hba1c levels	0	0.4621	4	In adults with type 2 diabetes, measure HbA1c levels at: 3–6-monthly intervals (tailored to individual needs), until the HbA1c is stable on unchanging therapy 6-monthly intervals once the HbA1c level and blood glucose lowering therapy are stable.	In adults with type 2 diabetes, if HbA1c levels are not adequately controlled by a single drug and rise to 58 mmol mol ( percent) or higher: reinforce advice about diet, lifestyle and adherence to drug treatment and support the person to aim for an HbA1c level of 53 mmol mol ( percent) and intensify drug treatment.	In adults with type 2 diabetes, measure HbA1c levels at: 3–6-monthly intervals (tailored to individual needs), until the HbA1c is stable on unchanging therapy 6-monthly intervals once the HbA1c level and blood glucose lowering therapy are stable.	In adults with type 2 diabetes, if HbA1c levels are not adequately controlled by a single drug and rise to 58 mmol mol ( percent) or higher: reinforce advice about diet, lifestyle and adherence to drug treatment and support the person to aim for an HbA1c level of 53 mmol mol ( percent) and intensify drug treatment.	
blood glucose	0	0.4556	18	In adults with type 2 diabetes, measure HbA1c levels at: 3–6-monthly intervals (tailored to individual needs), until the HbA1c is stable on unchanging therapy 6-monthly intervals once the HbA1c level and blood glucose lowering therapy are stable.	Last updated May 2017 on a case-by-case basis, with particular consideration for people who are older or frail, for adults with type 2 diabetes: who are unlikely to achieve longer-term risk-reduction benefits, for example, people with a reduced life expectancy for whom tight blood glucose control poses a high risk of the consequences of hypoglycaemia, for example, people who are at risk of falling, people who have impaired awareness of hypoglycaemia, and people who drive or operate machinery as part of their job for whom intensive management would not be appropriate, for example, people with significant comorbidities.	Take the Driver and Vehicle Licensing Agency (DVLA) At a glance guide to the current medical standards of fitness to drive into account when offering self-monitoring of blood glucose levels for adults with type 2 diabetes.	Do not routinely offer self-monitoring of blood glucose levels for adults with type 2 diabetes unless: the person is on insulin or there is evidence of hypoglycaemic episodes or the person is on oral medication that may increase their risk of hypoglycaemia while driving or operating machinery or	Consider short-term self-monitoring of blood glucose levels in adults with type 2 diabetes (and review treatment as necessary): when starting treatment with oral or intravenous corticosteroids or to confirm suspected hypoglycaemia.	If adults with type 2 diabetes are self-monitoring their blood glucose levels, carry out a structured assessment at least annually	The assessment should include: the person's self-monitoring skills the quality and frequency of testing checking that the person knows how to interpret the blood glucose results and what action to take the impact on the person's quality of life the continued benefit to the person the equipment used.	If an adult with type 2 diabetes is symptomatically hyperglycaemic, consider insulin (see recommendations – ) or a sulfonylurea, and review treatment when blood glucose control has been achieved.	Algorithm for blood glucose lowering therapy in adults with type 2 diabetes	In adults with type 2 diabetes, measure HbA1c levels at: 3–6-monthly intervals (tailored to individual needs), until the HbA1c is stable on unchanging therapy 6-monthly intervals once the HbA1c level and blood glucose lowering therapy are stable.	Last updated May 2017 on a case-by-case basis, with particular consideration for people who are older or frail, for adults with type 2 diabetes: who are unlikely to achieve longer-term risk-reduction benefits, for example, people with a reduced life expectancy for whom tight blood glucose control poses a high risk of the consequences of hypoglycaemia, for example, people who are at risk of falling, people who have impaired awareness of hypoglycaemia, and people who drive or operate machinery as part of their job for whom intensive management would not be appropriate, for example, people with significant comorbidities.	Take the Driver and Vehicle Licensing Agency (DVLA) At a glance guide to the current medical standards of fitness to drive into account when offering self-monitoring of blood glucose levels for adults with type 2 diabetes.	Do not routinely offer self-monitoring of blood glucose levels for adults with type 2 diabetes unless: the person is on insulin or there is evidence of hypoglycaemic episodes or the person is on oral medication that may increase their risk of hypoglycaemia while driving or operating machinery or	Consider short-term self-monitoring of blood glucose levels in adults with type 2 diabetes (and review treatment as necessary): when starting treatment with oral or intravenous corticosteroids or to confirm suspected hypoglycaemia.	If adults with type 2 diabetes are self-monitoring their blood glucose levels, carry out a structured assessment at least annually	The assessment should include: the person's self-monitoring skills the quality and frequency of testing checking that the person knows how to interpret the blood glucose results and what action to take the impact on the person's quality of life the continued benefit to the person the equipment used.	If an adult with type 2 diabetes is symptomatically hyperglycaemic, consider insulin (see recommendations – ) or a sulfonylurea, and review treatment when blood glucose control has been achieved.	Algorithm for blood glucose lowering therapy in adults with type 2 diabetes	
lifestyle advice	0	0.4079	8	For recommendations on lifestyle advice, see the NICE guidelines on: preventing excess weight gain, weight management, obesity, physical activity, smoking: brief interventions and referrals, stop smoking services, smoking: harm reduction, and smoking: acute, maternity and mental health services.	Offer and reinforce preventive lifestyle advice.	Provide lifestyle advice (see section in this guideline and the lifestyle interventions section in hypertension in adults NICE guideline CG127) if blood	Offer lifestyle advice and drug treatment to support adults with type 2 diabetes to achieve and maintain their HbA1c target (see section )	For recommendations on lifestyle advice, see the NICE guidelines on: preventing excess weight gain, weight management, obesity, physical activity, smoking: brief interventions and referrals, stop smoking services, smoking: harm reduction, and smoking: acute, maternity and mental health services.	Offer and reinforce preventive lifestyle advice.	Provide lifestyle advice (see section in this guideline and the lifestyle interventions section in hypertension in adults NICE guideline CG127) if blood	Offer lifestyle advice and drug treatment to support adults with type 2 diabetes to achieve and maintain their HbA1c target (see section )	
life expectancy	0	0.4058	4	Adopt an individualised approach to diabetes care that is tailored to the needs and circumstances of adults with type 2 diabetes, taking into account their personal preferences, comorbidities, risks from polypharmacy, and their ability to benefit from long-term interventions because of reduced life expectancy.	Last updated May 2017 on a case-by-case basis, with particular consideration for people who are older or frail, for adults with type 2 diabetes: who are unlikely to achieve longer-term risk-reduction benefits, for example, people with a reduced life expectancy for whom tight blood glucose control poses a high risk of the consequences of hypoglycaemia, for example, people who are at risk of falling, people who have impaired awareness of hypoglycaemia, and people who drive or operate machinery as part of their job for whom intensive management would not be appropriate, for example, people with significant comorbidities.	Adopt an individualised approach to diabetes care that is tailored to the needs and circumstances of adults with type 2 diabetes, taking into account their personal preferences, comorbidities, risks from polypharmacy, and their ability to benefit from long-term interventions because of reduced life expectancy.	Last updated May 2017 on a case-by-case basis, with particular consideration for people who are older or frail, for adults with type 2 diabetes: who are unlikely to achieve longer-term risk-reduction benefits, for example, people with a reduced life expectancy for whom tight blood glucose control poses a high risk of the consequences of hypoglycaemia, for example, people who are at risk of falling, people who have impaired awareness of hypoglycaemia, and people who drive or operate machinery as part of their job for whom intensive management would not be appropriate, for example, people with significant comorbidities.	
single drug	0	0.3983	4	For adults with type 2 diabetes managed either by lifestyle and diet, or by lifestyle and diet combined with a single drug not associated with hypoglycaemia, support the person to aim for an HbA1c level of 48 mmol mol ( percent)	In adults with type 2 diabetes, if HbA1c levels are not adequately controlled by a single drug and rise to 58 mmol mol ( percent) or higher: reinforce advice about diet, lifestyle and adherence to drug treatment and support the person to aim for an HbA1c level of 53 mmol mol ( percent) and intensify drug treatment.	For adults with type 2 diabetes managed either by lifestyle and diet, or by lifestyle and diet combined with a single drug not associated with hypoglycaemia, support the person to aim for an HbA1c level of 48 mmol mol ( percent)	In adults with type 2 diabetes, if HbA1c levels are not adequately controlled by a single drug and rise to 58 mmol mol ( percent) or higher: reinforce advice about diet, lifestyle and adherence to drug treatment and support the person to aim for an HbA1c level of 53 mmol mol ( percent) and intensify drug treatment.	
drug treatment	0	0.3927	22	For an adult with type 2 diabetes on antihypertensive drug treatment when diabetes is diagnosed, review blood pressure control and medications used.	First-line antihypertensive drug treatment should be a once-daily, generic angiotensin-converting enzyme (ACE) inhibitor	A calcium-channel blocker should be the first-line antihypertensive drug treatment for a woman for whom, after an informed discussion, it is agreed there is a possibility of her becoming pregnant.	Offer lifestyle advice and drug treatment to support adults with type 2 diabetes to achieve and maintain their HbA1c target (see section )	In adults with type 2 diabetes, if HbA1c levels are not adequately controlled by a single drug and rise to 58 mmol mol ( percent) or higher: reinforce advice about diet, lifestyle and adherence to drug treatment and support the person to aim for an HbA1c level of 53 mmol mol ( percent) and intensify drug treatment.	For adults with type 2 diabetes, discuss the benefits and risks of drug treatment, and the options available	Last updated May 2017 safety (see Medicines and Healthcare products Regulatory Agency MHRA guidance) and tolerability of the drug treatment(s) the person's individual clinical circumstances, for example, comorbidities, risks from polypharmacy the person's individual preferences and needs the licensed indications or combinations available cost (if 2 drugs in the same class are appropriate, choose the option with the lowest acquisition cost).	Offer standard-release metformin as the initial drug treatment for adults with type 2 diabetes.	In adults with type 2 diabetes, if metformin is contraindicated or not tolerated, consider initial drug treatment with: a dipeptidyl peptidase-4 (DPP-4) inhibitor or pioglitazone or a sulfonylurea.	In adults with type 2 diabetes, if initial drug treatment with metformin has not continued to control HbA1c to below the person's individually agreed threshold for intensification, consider dual therapy with: metformin and a DPP-4 inhibitor or metformin and pioglitazone or metformin and a sulfonylurea.	In adults with type 2 diabetes, if metformin is contraindicated or not tolerated and initial drug treatment has not continued to control HbA1c to below the person's individually agreed threshold for intensification, consider dual therapy with: a DPP-4 inhibitor and pioglitazone or a DPP-4 inhibitor and a sulfonylurea or pioglitazone and a sulfonylurea.	For an adult with type 2 diabetes on antihypertensive drug treatment when diabetes is diagnosed, review blood pressure control and medications used.	First-line antihypertensive drug treatment should be a once-daily, generic angiotensin-converting enzyme (ACE) inhibitor	A calcium-channel blocker should be the first-line antihypertensive drug treatment for a woman for whom, after an informed discussion, it is agreed there is a possibility of her becoming pregnant.	Offer lifestyle advice and drug treatment to support adults with type 2 diabetes to achieve and maintain their HbA1c target (see section )	In adults with type 2 diabetes, if HbA1c levels are not adequately controlled by a single drug and rise to 58 mmol mol ( percent) or higher: reinforce advice about diet, lifestyle and adherence to drug treatment and support the person to aim for an HbA1c level of 53 mmol mol ( percent) and intensify drug treatment.	For adults with type 2 diabetes, discuss the benefits and risks of drug treatment, and the options available	Last updated May 2017 safety (see Medicines and Healthcare products Regulatory Agency MHRA guidance) and tolerability of the drug treatment(s) the person's individual clinical circumstances, for example, comorbidities, risks from polypharmacy the person's individual preferences and needs the licensed indications or combinations available cost (if 2 drugs in the same class are appropriate, choose the option with the lowest acquisition cost).	Offer standard-release metformin as the initial drug treatment for adults with type 2 diabetes.	In adults with type 2 diabetes, if metformin is contraindicated or not tolerated, consider initial drug treatment with: a dipeptidyl peptidase-4 (DPP-4) inhibitor or pioglitazone or a sulfonylurea.	In adults with type 2 diabetes, if initial drug treatment with metformin has not continued to control HbA1c to below the person's individually agreed threshold for intensification, consider dual therapy with: metformin and a DPP-4 inhibitor or metformin and pioglitazone or metformin and a sulfonylurea.	In adults with type 2 diabetes, if metformin is contraindicated or not tolerated and initial drug treatment has not continued to control HbA1c to below the person's individually agreed threshold for intensification, consider dual therapy with: a DPP-4 inhibitor and pioglitazone or a DPP-4 inhibitor and a sulfonylurea or pioglitazone and a sulfonylurea.	
nice guidelines	0	0.3914	4	For recommendations on lifestyle advice, see the NICE guidelines on: preventing excess weight gain, weight management, obesity, physical activity, smoking: brief interventions and referrals, stop smoking services, smoking: harm reduction, and smoking: acute, maternity and mental health services.	For guidance on the primary and secondary prevention of cardiovascular disease in adults with type 2 diabetes, see the NICE guidelines on cardiovascular disease and myocardial infarction.	For recommendations on lifestyle advice, see the NICE guidelines on: preventing excess weight gain, weight management, obesity, physical activity, smoking: brief interventions and referrals, stop smoking services, smoking: harm reduction, and smoking: acute, maternity and mental health services.	For guidance on the primary and secondary prevention of cardiovascular disease in adults with type 2 diabetes, see the NICE guidelines on cardiovascular disease and myocardial infarction.	
insulin therapy	0	0.3515	8	If triple therapy with metformin and 2 other oral drugs (see recommendation ) is not effective, not tolerated or contraindicated, consider combination therapy with metformin, a sulfonylurea and a glucagon-like peptide-1 (GLP-1) mimetic for adults with type 2 diabetes who: have a BMI of 35 kg m2 or higher (adjust accordingly for people from black, Asian and other minority ethnic groups) and specific psychological or other medical problems associated with obesity or have a BMI lower than 35 kg m2and: for whom insulin therapy would have significant occupational implications or weight loss would benefit other significant obesity-related comorbidities.	When starting insulin therapy in adults with type 2 diabetes, use a structured programme employing active insulin dose titration that encompasses: injection technique, including rotating injection sites and avoiding repeated injections at the same point within sites continuing telephone support self-monitoring dose titration to target levels dietary understanding	When starting insulin therapy in adults with type 2 diabetes, continue to offer metformin for people without contraindications or intolerance	Start insulin therapy for adults with type 2 diabetes from a choice of a number of insulin types and regimens:	If triple therapy with metformin and 2 other oral drugs (see recommendation ) is not effective, not tolerated or contraindicated, consider combination therapy with metformin, a sulfonylurea and a glucagon-like peptide-1 (GLP-1) mimetic for adults with type 2 diabetes who: have a BMI of 35 kg m2 or higher (adjust accordingly for people from black, Asian and other minority ethnic groups) and specific psychological or other medical problems associated with obesity or have a BMI lower than 35 kg m2and: for whom insulin therapy would have significant occupational implications or weight loss would benefit other significant obesity-related comorbidities.	When starting insulin therapy in adults with type 2 diabetes, use a structured programme employing active insulin dose titration that encompasses: injection technique, including rotating injection sites and avoiding repeated injections at the same point within sites continuing telephone support self-monitoring dose titration to target levels dietary understanding	When starting insulin therapy in adults with type 2 diabetes, continue to offer metformin for people without contraindications or intolerance	Start insulin therapy for adults with type 2 diabetes from a choice of a number of insulin types and regimens:	
glucose measurements	0	0.3494	2	Investigate unexplained discrepancies between HbA1c and other glucose measurements	Investigate unexplained discrepancies between HbA1c and other glucose measurements	
individual hba1c	0	0.3494	2	Involve adults with type 2 diabetes in decisions about their individual HbA1c target	Involve adults with type 2 diabetes in decisions about their individual HbA1c target	
investigate unexplained	0	0.3494	2	Investigate unexplained discrepancies between HbA1c and other glucose measurements	Investigate unexplained discrepancies between HbA1c and other glucose measurements	
involve adults	0	0.3494	2	Involve adults with type 2 diabetes in decisions about their individual HbA1c target	Involve adults with type 2 diabetes in decisions about their individual HbA1c target	
measurements involve	0	0.3494	0	
offer lifestyle	0	0.3494	2	Offer lifestyle advice and drug treatment to support adults with type 2 diabetes to achieve and maintain their HbA1c target (see section )	Offer lifestyle advice and drug treatment to support adults with type 2 diabetes to achieve and maintain their HbA1c target (see section )	
target offer	0	0.3494	0	
unexplained discrepancies	0	0.3494	2	Investigate unexplained discrepancies between HbA1c and other glucose measurements	Investigate unexplained discrepancies between HbA1c and other glucose measurements	
excess weight	0	0.3333	2	For recommendations on lifestyle advice, see the NICE guidelines on: preventing excess weight gain, weight management, obesity, physical activity, smoking: brief interventions and referrals, stop smoking services, smoking: harm reduction, and smoking: acute, maternity and mental health services.	For recommendations on lifestyle advice, see the NICE guidelines on: preventing excess weight gain, weight management, obesity, physical activity, smoking: brief interventions and referrals, stop smoking services, smoking: harm reduction, and smoking: acute, maternity and mental health services.	
harm reduction	0	0.3333	2	For recommendations on lifestyle advice, see the NICE guidelines on: preventing excess weight gain, weight management, obesity, physical activity, smoking: brief interventions and referrals, stop smoking services, smoking: harm reduction, and smoking: acute, maternity and mental health services.	For recommendations on lifestyle advice, see the NICE guidelines on: preventing excess weight gain, weight management, obesity, physical activity, smoking: brief interventions and referrals, stop smoking services, smoking: harm reduction, and smoking: acute, maternity and mental health services.	
health services	1	0.3333	2	For recommendations on lifestyle advice, see the NICE guidelines on: preventing excess weight gain, weight management, obesity, physical activity, smoking: brief interventions and referrals, stop smoking services, smoking: harm reduction, and smoking: acute, maternity and mental health services.	For recommendations on lifestyle advice, see the NICE guidelines on: preventing excess weight gain, weight management, obesity, physical activity, smoking: brief interventions and referrals, stop smoking services, smoking: harm reduction, and smoking: acute, maternity and mental health services.	
licensed non-metformin-based	0	0.3333	2	However, discuss with any person for whom repaglinide is being considered, that there is no licensed non-metformin-based combination containing repaglinide that can be offered at first intensification.	However, discuss with any person for whom repaglinide is being considered, that there is no licensed non-metformin-based combination containing repaglinide that can be offered at first intensification.	
mental health	1	0.3333	2	For recommendations on lifestyle advice, see the NICE guidelines on: preventing excess weight gain, weight management, obesity, physical activity, smoking: brief interventions and referrals, stop smoking services, smoking: harm reduction, and smoking: acute, maternity and mental health services.	For recommendations on lifestyle advice, see the NICE guidelines on: preventing excess weight gain, weight management, obesity, physical activity, smoking: brief interventions and referrals, stop smoking services, smoking: harm reduction, and smoking: acute, maternity and mental health services.	
non-metformin-based combination	0	0.3333	2	However, discuss with any person for whom repaglinide is being considered, that there is no licensed non-metformin-based combination containing repaglinide that can be offered at first intensification.	However, discuss with any person for whom repaglinide is being considered, that there is no licensed non-metformin-based combination containing repaglinide that can be offered at first intensification.	
physical activity	0	0.3333	2	For recommendations on lifestyle advice, see the NICE guidelines on: preventing excess weight gain, weight management, obesity, physical activity, smoking: brief interventions and referrals, stop smoking services, smoking: harm reduction, and smoking: acute, maternity and mental health services.	For recommendations on lifestyle advice, see the NICE guidelines on: preventing excess weight gain, weight management, obesity, physical activity, smoking: brief interventions and referrals, stop smoking services, smoking: harm reduction, and smoking: acute, maternity and mental health services.	
smoking services	0	0.3333	2	For recommendations on lifestyle advice, see the NICE guidelines on: preventing excess weight gain, weight management, obesity, physical activity, smoking: brief interventions and referrals, stop smoking services, smoking: harm reduction, and smoking: acute, maternity and mental health services.	For recommendations on lifestyle advice, see the NICE guidelines on: preventing excess weight gain, weight management, obesity, physical activity, smoking: brief interventions and referrals, stop smoking services, smoking: harm reduction, and smoking: acute, maternity and mental health services.	
weight gain	0	0.3333	2	For recommendations on lifestyle advice, see the NICE guidelines on: preventing excess weight gain, weight management, obesity, physical activity, smoking: brief interventions and referrals, stop smoking services, smoking: harm reduction, and smoking: acute, maternity and mental health services.	For recommendations on lifestyle advice, see the NICE guidelines on: preventing excess weight gain, weight management, obesity, physical activity, smoking: brief interventions and referrals, stop smoking services, smoking: harm reduction, and smoking: acute, maternity and mental health services.	
weight management	0	0.3333	2	For recommendations on lifestyle advice, see the NICE guidelines on: preventing excess weight gain, weight management, obesity, physical activity, smoking: brief interventions and referrals, stop smoking services, smoking: harm reduction, and smoking: acute, maternity and mental health services.	For recommendations on lifestyle advice, see the NICE guidelines on: preventing excess weight gain, weight management, obesity, physical activity, smoking: brief interventions and referrals, stop smoking services, smoking: harm reduction, and smoking: acute, maternity and mental health services.	
cerebrovascular damage	0	0.329	2	Repeat blood pressure measurements within: 1 month if blood pressure is higher than 150 90 mmHg 2 months if blood pressure is higher than 140 80 mmHg 2 months if blood pressure is higher than 130 80 mmHg and there is kidney, eye or cerebrovascular damage.	Repeat blood pressure measurements within: 1 month if blood pressure is higher than 150 90 mmHg 2 months if blood pressure is higher than 140 80 mmHg 2 months if blood pressure is higher than 130 80 mmHg and there is kidney, eye or cerebrovascular damage.	
pressure measurements	0	0.329	2	Repeat blood pressure measurements within: 1 month if blood pressure is higher than 150 90 mmHg 2 months if blood pressure is higher than 140 80 mmHg 2 months if blood pressure is higher than 130 80 mmHg and there is kidney, eye or cerebrovascular damage.	Repeat blood pressure measurements within: 1 month if blood pressure is higher than 150 90 mmHg 2 months if blood pressure is higher than 140 80 mmHg 2 months if blood pressure is higher than 130 80 mmHg and there is kidney, eye or cerebrovascular damage.	
repeat blood	0	0.329	2	Repeat blood pressure measurements within: 1 month if blood pressure is higher than 150 90 mmHg 2 months if blood pressure is higher than 140 80 mmHg 2 months if blood pressure is higher than 130 80 mmHg and there is kidney, eye or cerebrovascular damage.	Repeat blood pressure measurements within: 1 month if blood pressure is higher than 150 90 mmHg 2 months if blood pressure is higher than 140 80 mmHg 2 months if blood pressure is higher than 130 80 mmHg and there is kidney, eye or cerebrovascular damage.	
nph insulin	1	0.3286	4	Consider switching to insulin detemir or insulin glargine from NPH insulin in adults with type 2 diabetes: who do not reach their target HbA1c because of significant hypoglycaemia or who experience significant hypoglycaemia on NPH insulin irrespective of the level of	Monitor adults with type 2 diabetes who are on a basal insulin regimen (NPH insulin, insulin detemir or insulin glargine ) for the need for short-acting insulin before meals (or a pre-mixed biphasic insulin preparation).	Consider switching to insulin detemir or insulin glargine from NPH insulin in adults with type 2 diabetes: who do not reach their target HbA1c because of significant hypoglycaemia or who experience significant hypoglycaemia on NPH insulin irrespective of the level of	Monitor adults with type 2 diabetes who are on a basal insulin regimen (NPH insulin, insulin detemir or insulin glargine ) for the need for short-acting insulin before meals (or a pre-mixed biphasic insulin preparation).	
conditions notice-of-rights	0	0.273	32	Type 2 diabetes in adults: management (NG28) conditions notice-of-rights)	Type 2 diabetes in adults: management (NG28) conditions notice-of-rights)	Type 2 diabetes in adults: management (NG28) conditions notice-of-rights)	Type 2 diabetes in adults: management (NG28) conditions notice-of-rights)	Type 2 diabetes in adults: management (NG28) conditions notice-of-rights)	Type 2 diabetes in adults: management (NG28) conditions notice-of-rights)	Type 2 diabetes in adults: management (NG28) conditions notice-of-rights)	Type 2 diabetes in adults: management (NG28) conditions notice-of-rights)	Type 2 diabetes in adults: management (NG28) conditions notice-of-rights)	Type 2 diabetes in adults: management (NG28) conditions notice-of-rights)	Type 2 diabetes in adults: management (NG28) conditions notice-of-rights)	Type 2 diabetes in adults: management (NG28) conditions notice-of-rights)	Type 2 diabetes in adults: management (NG28) conditions notice-of-rights)	Type 2 diabetes in adults: management (NG28) conditions notice-of-rights)	Type 2 diabetes in adults: management (NG28) conditions notice-of-rights)	Type 2 diabetes in adults: management (NG28) conditions notice-of-rights)	Type 2 diabetes in adults: management (NG28) conditions notice-of-rights)	Type 2 diabetes in adults: management (NG28) conditions notice-of-rights)	Type 2 diabetes in adults: management (NG28) conditions notice-of-rights)	Type 2 diabetes in adults: management (NG28) conditions notice-of-rights)	Type 2 diabetes in adults: management (NG28) conditions notice-of-rights)	Type 2 diabetes in adults: management (NG28) conditions notice-of-rights)	Type 2 diabetes in adults: management (NG28) conditions notice-of-rights)	Type 2 diabetes in adults: management (NG28) conditions notice-of-rights)	Type 2 diabetes in adults: management (NG28) conditions notice-of-rights)	Type 2 diabetes in adults: management (NG28) conditions notice-of-rights)	Type 2 diabetes in adults: management (NG28) conditions notice-of-rights)	Type 2 diabetes in adults: management (NG28) conditions notice-of-rights)	Type 2 diabetes in adults: management (NG28) conditions notice-of-rights)	Type 2 diabetes in adults: management (NG28) conditions notice-of-rights)	Type 2 diabetes in adults: management (NG28) conditions notice-of-rights)	Type 2 diabetes in adults: management (NG28) conditions notice-of-rights)	
type 2	1	0.245	132	Be aware that, if metformin is contraindicated or not tolerated, repaglinide is both clinically effective and cost effective in adults with type 2 diabetes	Type 2 diabetes in adults: management (NG28) conditions notice-of-rights)	Adopt an individualised approach to diabetes care that is tailored to the needs and circumstances of adults with type 2 diabetes, taking into account their personal preferences, comorbidities, risks from polypharmacy, and their ability to benefit from long-term interventions because of reduced life expectancy.	Take into account any disabilities, including visual impairment, when planning and delivering care for adults with type 2 diabetes.	Offer structured education to adults with type 2 diabetes and or their family members or carers (as appropriate) at and around the time of diagnosis, with	Type 2 diabetes in adults: management (NG28) conditions notice-of-rights)	Ensure that any structured education programme for adults with type 2 diabetes includes the following components:	Ensure that all members of the diabetes healthcare team are familiar with the patient-education programmes available locally, that these programmes are integrated with the rest of the care pathway, and that adults with type 2 diabetes and their family members or carers (as appropriate) have the opportunity to contribute to the design and provision of local programmes.	Type 2 diabetes in adults: management (NG28) conditions notice-of-rights)	Emphasise advice on healthy balanced eating that is applicable to the general population when providing advice to adults with type 2 diabetes	For adults with type 2 diabetes who are overweight, set an initial body weight loss target of 5–10percent	Advise adults with type 2 diabetes that limited substitution of sucrose-containing foods for other carbohydrate in the meal plan is allowable, but that they should take care to avoid excess energy intake.	Type 2 diabetes in adults: management (NG28) conditions notice-of-rights)	When adults with type 2 diabetes are admitted to hospital as inpatients or to any other care setting, implement a meal planning system that provides consistency in the carbohydrate content of meals and snacks.	For recommendations on bariatric surgery for people with recent-onset type 2 diabetes, see the section on bariatric surgery for people with recent-onset type 2 diabetes in the NICE guideline on obesity.	Measure blood pressure at least annually in an adult with type 2 diabetes without previously diagnosed hypertension or renal disease	For an adult with type 2 diabetes on antihypertensive drug treatment when diabetes is diagnosed, review blood pressure control and medications used.	Type 2 diabetes in adults: management (NG28) conditions notice-of-rights)	Type 2 diabetes in adults: management (NG28) conditions notice-of-rights)	Do not offer antiplatelet therapy (aspirin or clopidogrel) for adults with type 2 diabetes without cardiovascular disease.	For guidance on the primary and secondary prevention of cardiovascular disease in adults with type 2 diabetes, see the NICE guidelines on cardiovascular disease and myocardial infarction.	In adults with type 2 diabetes, measure HbA1c levels at: 3–6-monthly intervals (tailored to individual needs), until the HbA1c is stable on unchanging therapy 6-monthly intervals once the HbA1c level and blood glucose lowering therapy are stable.	Type 2 diabetes in adults: management (NG28) conditions notice-of-rights)	Involve adults with type 2 diabetes in decisions about their individual HbA1c target	Offer lifestyle advice and drug treatment to support adults with type 2 diabetes to achieve and maintain their HbA1c target (see section )	For adults with type 2 diabetes managed either by lifestyle and diet, or by lifestyle and diet combined with a single drug not associated with hypoglycaemia, support the person to aim for an HbA1c level of 48 mmol mol ( percent)	In adults with type 2 diabetes, if HbA1c levels are not adequately controlled by a single drug and rise to 58 mmol mol ( percent) or higher: reinforce advice about diet, lifestyle and adherence to drug treatment and support the person to aim for an HbA1c level of 53 mmol mol ( percent) and intensify drug treatment.	Type 2 diabetes in adults: management (NG28) conditions notice-of-rights)	Last updated May 2017 on a case-by-case basis, with particular consideration for people who are older or frail, for adults with type 2 diabetes: who are unlikely to achieve longer-term risk-reduction benefits, for example, people with a reduced life expectancy for whom tight blood glucose control poses a high risk of the consequences of hypoglycaemia, for example, people who are at risk of falling, people who have impaired awareness of hypoglycaemia, and people who drive or operate machinery as part of their job for whom intensive management would not be appropriate, for example, people with significant comorbidities.	If adults with type 2 diabetes achieve an HbA1c level that is lower than their target and they are not experiencing hypoglycaemia, encourage them to maintain it	For guidance on HbA1c targets for women with type 2 diabetes who are pregnant or planning to become pregnant, see the NICE guideline on diabetes in pregnancy.	Take the Driver and Vehicle Licensing Agency (DVLA) At a glance guide to the current medical standards of fitness to drive into account when offering self-monitoring of blood glucose levels for adults with type 2 diabetes.	Do not routinely offer self-monitoring of blood glucose levels for adults with type 2 diabetes unless: the person is on insulin or there is evidence of hypoglycaemic episodes or the person is on oral medication that may increase their risk of hypoglycaemia while driving or operating machinery or	Type 2 diabetes in adults: management (NG28) conditions notice-of-rights)	Consider short-term self-monitoring of blood glucose levels in adults with type 2 diabetes (and review treatment as necessary): when starting treatment with oral or intravenous corticosteroids or to confirm suspected hypoglycaemia.	Be aware that adults with type 2 diabetes who have acute intercurrent illness are at risk of worsening hyperglycaemia	If adults with type 2 diabetes are self-monitoring their blood glucose levels, carry out a structured assessment at least annually	For adults with type 2 diabetes, discuss the benefits and risks of drug treatment, and the options available	Type 2 diabetes in adults: management (NG28) conditions notice-of-rights)	If an adult with type 2 diabetes is symptomatically hyperglycaemic, consider insulin (see recommendations – ) or a sulfonylurea, and review treatment when blood glucose control has been achieved.	Offer standard-release metformin as the initial drug treatment for adults with type 2 diabetes.	Gradually increase the dose of standard-release metformin over several weeks to minimise the risk of gastrointestinal side effects in adults with type 2 diabetes.	If an adult with type 2 diabetes experiences gastrointestinal side effects with standard-release metformin, consider a trial of modified-release metformin.	Algorithm for blood glucose lowering therapy in adults with type 2 diabetes	Type 2 diabetes in adults: management (NG28) conditions notice-of-rights)	In adults with type 2 diabetes, review the dose of metformin if the estimated glomerular filtration rate (eGFR) is below 45 ml minute m2:	In adults with type 2 diabetes, if metformin is contraindicated or not tolerated, consider initial drug treatment with: a dipeptidyl peptidase-4 (DPP-4) inhibitor or pioglitazone or a sulfonylurea.	In adults with type 2 diabetes, do not offer or continue pioglitazone if they have any of the following: heart failure or history of heart failure	Type 2 diabetes in adults: management (NG28) conditions notice-of-rights)	Treatment with sodium–glucose cotransporter 2 (SGLT-2) inhibitors , may be appropriate for some adults with type 2 diabetes if metformin is contraindicated or not tolerated (see NICE's guidance on canagliflozin, dapagliflozin and empagliflozin as monotherapies for treating type 2 diabetes).	In adults with type 2 diabetes, if initial drug treatment with metformin has not continued to control HbA1c to below the person's individually agreed threshold for intensification, consider dual therapy with: metformin and a DPP-4 inhibitor or metformin and pioglitazone or metformin and a sulfonylurea.	In adults with type 2 diabetes, if metformin is contraindicated or not tolerated and initial drug treatment has not continued to control HbA1c to below the person's individually agreed threshold for intensification, consider dual therapy with: a DPP-4 inhibitor and pioglitazone or a DPP-4 inhibitor and a sulfonylurea or pioglitazone and a sulfonylurea.	Type 2 diabetes in adults: management (NG28) conditions notice-of-rights)	In adults with type 2 diabetes, if dual therapy with metformin and another oral drug (see recommendation ) has not continued to control HbA1c to below the person's individually agreed threshold for intensification, consider either: triple therapy with: metformin, a DPP-4 inhibitor and a sulfonylurea or metformin, pioglitazone and a sulfonylurea or starting insulin-based treatment (see recommendations – ).	If triple therapy with metformin and 2 other oral drugs (see recommendation ) is not effective, not tolerated or contraindicated, consider combination therapy with metformin, a sulfonylurea and a glucagon-like peptide-1 (GLP-1) mimetic for adults with type 2 diabetes who: have a BMI of 35 kg m2 or higher (adjust accordingly for people from black, Asian and other minority ethnic groups) and specific psychological or other medical problems associated with obesity or have a BMI lower than 35 kg m2and: for whom insulin therapy would have significant occupational implications or weight loss would benefit other significant obesity-related comorbidities.	In adults with type 2 diabetes, if metformin is contraindicated or not tolerated, and if dual therapy with 2 oral drugs (see recommendation ) has not continued to control HbA1c to below the person's individually agreed threshold for intensification, consider insulin-based treatment (see recommendations – ).	Type 2 diabetes in adults: management (NG28) conditions notice-of-rights)	In adults with type 2 diabetes, only offer a GLP-1 mimetic in combination with insulin with specialist care advice and ongoing support from a consultant-led multidisciplinary team .	When starting insulin therapy in adults with type 2 diabetes, use a structured programme employing active insulin dose titration that encompasses: injection technique, including rotating injection sites and avoiding repeated injections at the same point within sites continuing telephone support self-monitoring dose titration to target levels dietary understanding	When starting insulin therapy in adults with type 2 diabetes, continue to offer metformin for people without contraindications or intolerance	Start insulin therapy for adults with type 2 diabetes from a choice of a number of insulin types and regimens:	Type 2 diabetes in adults: management (NG28) conditions notice-of-rights)	Consider switching to insulin detemir or insulin glargine from NPH insulin in adults with type 2 diabetes: who do not reach their target HbA1c because of significant hypoglycaemia or who experience significant hypoglycaemia on NPH insulin irrespective of the level of	Type 2 diabetes in adults: management (NG28) conditions notice-of-rights)	Monitor adults with type 2 diabetes who are on a basal insulin regimen (NPH insulin, insulin detemir or insulin glargine ) for the need for short-acting insulin before meals (or a pre-mixed biphasic insulin preparation).	Monitor adults with type 2 diabetes who are on pre-mixed (biphasic) insulin for the need for a further injection of short-acting insulin befor	Be aware that, if metformin is contraindicated or not tolerated, repaglinide is both clinically effective and cost effective in adults with type 2 diabetes	Type 2 diabetes in adults: management (NG28) conditions notice-of-rights)	Adopt an individualised approach to diabetes care that is tailored to the needs and circumstances of adults with type 2 diabetes, taking into account their personal preferences, comorbidities, risks from polypharmacy, and their ability to benefit from long-term interventions because of reduced life expectancy.	Take into account any disabilities, including visual impairment, when planning and delivering care for adults with type 2 diabetes.	Offer structured education to adults with type 2 diabetes and or their family members or carers (as appropriate) at and around the time of diagnosis, with	Type 2 diabetes in adults: management (NG28) conditions notice-of-rights)	Ensure that any structured education programme for adults with type 2 diabetes includes the following components:	Ensure that all members of the diabetes healthcare team are familiar with the patient-education programmes available locally, that these programmes are integrated with the rest of the care pathway, and that adults with type 2 diabetes and their family members or carers (as appropriate) have the opportunity to contribute to the design and provision of local programmes.	Type 2 diabetes in adults: management (NG28) conditions notice-of-rights)	Emphasise advice on healthy balanced eating that is applicable to the general population when providing advice to adults with type 2 diabetes	For adults with type 2 diabetes who are overweight, set an initial body weight loss target of 5–10percent	Advise adults with type 2 diabetes that limited substitution of sucrose-containing foods for other carbohydrate in the meal plan is allowable, but that they should take care to avoid excess energy intake.	Type 2 diabetes in adults: management (NG28) conditions notice-of-rights)	When adults with type 2 diabetes are admitted to hospital as inpatients or to any other care setting, implement a meal planning system that provides consistency in the carbohydrate content of meals and snacks.	For recommendations on bariatric surgery for people with recent-onset type 2 diabetes, see the section on bariatric surgery for people with recent-onset type 2 diabetes in the NICE guideline on obesity.	Measure blood pressure at least annually in an adult with type 2 diabetes without previously diagnosed hypertension or renal disease	For an adult with type 2 diabetes on antihypertensive drug treatment when diabetes is diagnosed, review blood pressure control and medications used.	Type 2 diabetes in adults: management (NG28) conditions notice-of-rights)	Type 2 diabetes in adults: management (NG28) conditions notice-of-rights)	Do not offer antiplatelet therapy (aspirin or clopidogrel) for adults with type 2 diabetes without cardiovascular disease.	For guidance on the primary and secondary prevention of cardiovascular disease in adults with type 2 diabetes, see the NICE guidelines on cardiovascular disease and myocardial infarction.	In adults with type 2 diabetes, measure HbA1c levels at: 3–6-monthly intervals (tailored to individual needs), until the HbA1c is stable on unchanging therapy 6-monthly intervals once the HbA1c level and blood glucose lowering therapy are stable.	Type 2 diabetes in adults: management (NG28) conditions notice-of-rights)	Involve adults with type 2 diabetes in decisions about their individual HbA1c target	Offer lifestyle advice and drug treatment to support adults with type 2 diabetes to achieve and maintain their HbA1c target (see section )	For adults with type 2 diabetes managed either by lifestyle and diet, or by lifestyle and diet combined with a single drug not associated with hypoglycaemia, support the person to aim for an HbA1c level of 48 mmol mol ( percent)	In adults with type 2 diabetes, if HbA1c levels are not adequately controlled by a single drug and rise to 58 mmol mol ( percent) or higher: reinforce advice about diet, lifestyle and adherence to drug treatment and support the person to aim for an HbA1c level of 53 mmol mol ( percent) and intensify drug treatment.	Type 2 diabetes in adults: management (NG28) conditions notice-of-rights)	Last updated May 2017 on a case-by-case basis, with particular consideration for people who are older or frail, for adults with type 2 diabetes: who are unlikely to achieve longer-term risk-reduction benefits, for example, people with a reduced life expectancy for whom tight blood glucose control poses a high risk of the consequences of hypoglycaemia, for example, people who are at risk of falling, people who have impaired awareness of hypoglycaemia, and people who drive or operate machinery as part of their job for whom intensive management would not be appropriate, for example, people with significant comorbidities.	If adults with type 2 diabetes achieve an HbA1c level that is lower than their target and they are not experiencing hypoglycaemia, encourage them to maintain it	For guidance on HbA1c targets for women with type 2 diabetes who are pregnant or planning to become pregnant, see the NICE guideline on diabetes in pregnancy.	Take the Driver and Vehicle Licensing Agency (DVLA) At a glance guide to the current medical standards of fitness to drive into account when offering self-monitoring of blood glucose levels for adults with type 2 diabetes.	Do not routinely offer self-monitoring of blood glucose levels for adults with type 2 diabetes unless: the person is on insulin or there is evidence of hypoglycaemic episodes or the person is on oral medication that may increase their risk of hypoglycaemia while driving or operating machinery or	Type 2 diabetes in adults: management (NG28) conditions notice-of-rights)	Consider short-term self-monitoring of blood glucose levels in adults with type 2 diabetes (and review treatment as necessary): when starting treatment with oral or intravenous corticosteroids or to confirm suspected hypoglycaemia.	Be aware that adults with type 2 diabetes who have acute intercurrent illness are at risk of worsening hyperglycaemia	If adults with type 2 diabetes are self-monitoring their blood glucose levels, carry out a structured assessment at least annually	For adults with type 2 diabetes, discuss the benefits and risks of drug treatment, and the options available	Type 2 diabetes in adults: management (NG28) conditions notice-of-rights)	If an adult with type 2 diabetes is symptomatically hyperglycaemic, consider insulin (see recommendations – ) or a sulfonylurea, and review treatment when blood glucose control has been achieved.	Offer standard-release metformin as the initial drug treatment for adults with type 2 diabetes.	Gradually increase the dose of standard-release metformin over several weeks to minimise the risk of gastrointestinal side effects in adults with type 2 diabetes.	If an adult with type 2 diabetes experiences gastrointestinal side effects with standard-release metformin, consider a trial of modified-release metformin.	Algorithm for blood glucose lowering therapy in adults with type 2 diabetes	Type 2 diabetes in adults: management (NG28) conditions notice-of-rights)	In adults with type 2 diabetes, review the dose of metformin if the estimated glomerular filtration rate (eGFR) is below 45 ml minute m2:	In adults with type 2 diabetes, if metformin is contraindicated or not tolerated, consider initial drug treatment with: a dipeptidyl peptidase-4 (DPP-4) inhibitor or pioglitazone or a sulfonylurea.	In adults with type 2 diabetes, do not offer or continue pioglitazone if they have any of the following: heart failure or history of heart failure	Type 2 diabetes in adults: management (NG28) conditions notice-of-rights)	Treatment with sodium–glucose cotransporter 2 (SGLT-2) inhibitors , may be appropriate for some adults with type 2 diabetes if metformin is contraindicated or not tolerated (see NICE's guidance on canagliflozin, dapagliflozin and empagliflozin as monotherapies for treating type 2 diabetes).	In adults with type 2 diabetes, if initial drug treatment with metformin has not continued to control HbA1c to below the person's individually agreed threshold for intensification, consider dual therapy with: metformin and a DPP-4 inhibitor or metformin and pioglitazone or metformin and a sulfonylurea.	In adults with type 2 diabetes, if metformin is contraindicated or not tolerated and initial drug treatment has not continued to control HbA1c to below the person's individually agreed threshold for intensification, consider dual therapy with: a DPP-4 inhibitor and pioglitazone or a DPP-4 inhibitor and a sulfonylurea or pioglitazone and a sulfonylurea.	Type 2 diabetes in adults: management (NG28) conditions notice-of-rights)	In adults with type 2 diabetes, if dual therapy with metformin and another oral drug (see recommendation ) has not continued to control HbA1c to below the person's individually agreed threshold for intensification, consider either: triple therapy with: metformin, a DPP-4 inhibitor and a sulfonylurea or metformin, pioglitazone and a sulfonylurea or starting insulin-based treatment (see recommendations – ).	If triple therapy with metformin and 2 other oral drugs (see recommendation ) is not effective, not tolerated or contraindicated, consider combination therapy with metformin, a sulfonylurea and a glucagon-like peptide-1 (GLP-1) mimetic for adults with type 2 diabetes who: have a BMI of 35 kg m2 or higher (adjust accordingly for people from black, Asian and other minority ethnic groups) and specific psychological or other medical problems associated with obesity or have a BMI lower than 35 kg m2and: for whom insulin therapy would have significant occupational implications or weight loss would benefit other significant obesity-related comorbidities.	In adults with type 2 diabetes, if metformin is contraindicated or not tolerated, and if dual therapy with 2 oral drugs (see recommendation ) has not continued to control HbA1c to below the person's individually agreed threshold for intensification, consider insulin-based treatment (see recommendations – ).	Type 2 diabetes in adults: management (NG28) conditions notice-of-rights)	In adults with type 2 diabetes, only offer a GLP-1 mimetic in combination with insulin with specialist care advice and ongoing support from a consultant-led multidisciplinary team .	When starting insulin therapy in adults with type 2 diabetes, use a structured programme employing active insulin dose titration that encompasses: injection technique, including rotating injection sites and avoiding repeated injections at the same point within sites continuing telephone support self-monitoring dose titration to target levels dietary understanding	When starting insulin therapy in adults with type 2 diabetes, continue to offer metformin for people without contraindications or intolerance	Start insulin therapy for adults with type 2 diabetes from a choice of a number of insulin types and regimens:	Type 2 diabetes in adults: management (NG28) conditions notice-of-rights)	Consider switching to insulin detemir or insulin glargine from NPH insulin in adults with type 2 diabetes: who do not reach their target HbA1c because of significant hypoglycaemia or who experience significant hypoglycaemia on NPH insulin irrespective of the level of	Type 2 diabetes in adults: management (NG28) conditions notice-of-rights)	Monitor adults with type 2 diabetes who are on a basal insulin regimen (NPH insulin, insulin detemir or insulin glargine ) for the need for short-acting insulin before meals (or a pre-mixed biphasic insulin preparation).	Monitor adults with type 2 diabetes who are on pre-mixed (biphasic) insulin for the need for a further injection of short-acting insulin befor	
case-by-case basis	0	0.2391	2	Last updated May 2017 on a case-by-case basis, with particular consideration for people who are older or frail, for adults with type 2 diabetes: who are unlikely to achieve longer-term risk-reduction benefits, for example, people with a reduced life expectancy for whom tight blood glucose control poses a high risk of the consequences of hypoglycaemia, for example, people who are at risk of falling, people who have impaired awareness of hypoglycaemia, and people who drive or operate machinery as part of their job for whom intensive management would not be appropriate, for example, people with significant comorbidities.	Last updated May 2017 on a case-by-case basis, with particular consideration for people who are older or frail, for adults with type 2 diabetes: who are unlikely to achieve longer-term risk-reduction benefits, for example, people with a reduced life expectancy for whom tight blood glucose control poses a high risk of the consequences of hypoglycaemia, for example, people who are at risk of falling, people who have impaired awareness of hypoglycaemia, and people who drive or operate machinery as part of their job for whom intensive management would not be appropriate, for example, people with significant comorbidities.	
high risk	0	0.2391	2	Last updated May 2017 on a case-by-case basis, with particular consideration for people who are older or frail, for adults with type 2 diabetes: who are unlikely to achieve longer-term risk-reduction benefits, for example, people with a reduced life expectancy for whom tight blood glucose control poses a high risk of the consequences of hypoglycaemia, for example, people who are at risk of falling, people who have impaired awareness of hypoglycaemia, and people who drive or operate machinery as part of their job for whom intensive management would not be appropriate, for example, people with significant comorbidities.	Last updated May 2017 on a case-by-case basis, with particular consideration for people who are older or frail, for adults with type 2 diabetes: who are unlikely to achieve longer-term risk-reduction benefits, for example, people with a reduced life expectancy for whom tight blood glucose control poses a high risk of the consequences of hypoglycaemia, for example, people who are at risk of falling, people who have impaired awareness of hypoglycaemia, and people who drive or operate machinery as part of their job for whom intensive management would not be appropriate, for example, people with significant comorbidities.	
intensive management	0	0.2391	2	Last updated May 2017 on a case-by-case basis, with particular consideration for people who are older or frail, for adults with type 2 diabetes: who are unlikely to achieve longer-term risk-reduction benefits, for example, people with a reduced life expectancy for whom tight blood glucose control poses a high risk of the consequences of hypoglycaemia, for example, people who are at risk of falling, people who have impaired awareness of hypoglycaemia, and people who drive or operate machinery as part of their job for whom intensive management would not be appropriate, for example, people with significant comorbidities.	Last updated May 2017 on a case-by-case basis, with particular consideration for people who are older or frail, for adults with type 2 diabetes: who are unlikely to achieve longer-term risk-reduction benefits, for example, people with a reduced life expectancy for whom tight blood glucose control poses a high risk of the consequences of hypoglycaemia, for example, people who are at risk of falling, people who have impaired awareness of hypoglycaemia, and people who drive or operate machinery as part of their job for whom intensive management would not be appropriate, for example, people with significant comorbidities.	
risk-reduction benefits	0	0.2391	2	Last updated May 2017 on a case-by-case basis, with particular consideration for people who are older or frail, for adults with type 2 diabetes: who are unlikely to achieve longer-term risk-reduction benefits, for example, people with a reduced life expectancy for whom tight blood glucose control poses a high risk of the consequences of hypoglycaemia, for example, people who are at risk of falling, people who have impaired awareness of hypoglycaemia, and people who drive or operate machinery as part of their job for whom intensive management would not be appropriate, for example, people with significant comorbidities.	Last updated May 2017 on a case-by-case basis, with particular consideration for people who are older or frail, for adults with type 2 diabetes: who are unlikely to achieve longer-term risk-reduction benefits, for example, people with a reduced life expectancy for whom tight blood glucose control poses a high risk of the consequences of hypoglycaemia, for example, people who are at risk of falling, people who have impaired awareness of hypoglycaemia, and people who drive or operate machinery as part of their job for whom intensive management would not be appropriate, for example, people with significant comorbidities.	
significant comorbidities	0	0.2391	2	Last updated May 2017 on a case-by-case basis, with particular consideration for people who are older or frail, for adults with type 2 diabetes: who are unlikely to achieve longer-term risk-reduction benefits, for example, people with a reduced life expectancy for whom tight blood glucose control poses a high risk of the consequences of hypoglycaemia, for example, people who are at risk of falling, people who have impaired awareness of hypoglycaemia, and people who drive or operate machinery as part of their job for whom intensive management would not be appropriate, for example, people with significant comorbidities.	Last updated May 2017 on a case-by-case basis, with particular consideration for people who are older or frail, for adults with type 2 diabetes: who are unlikely to achieve longer-term risk-reduction benefits, for example, people with a reduced life expectancy for whom tight blood glucose control poses a high risk of the consequences of hypoglycaemia, for example, people who are at risk of falling, people who have impaired awareness of hypoglycaemia, and people who drive or operate machinery as part of their job for whom intensive management would not be appropriate, for example, people with significant comorbidities.	
tight blood	0	0.2391	2	Last updated May 2017 on a case-by-case basis, with particular consideration for people who are older or frail, for adults with type 2 diabetes: who are unlikely to achieve longer-term risk-reduction benefits, for example, people with a reduced life expectancy for whom tight blood glucose control poses a high risk of the consequences of hypoglycaemia, for example, people who are at risk of falling, people who have impaired awareness of hypoglycaemia, and people who drive or operate machinery as part of their job for whom intensive management would not be appropriate, for example, people with significant comorbidities.	Last updated May 2017 on a case-by-case basis, with particular consideration for people who are older or frail, for adults with type 2 diabetes: who are unlikely to achieve longer-term risk-reduction benefits, for example, people with a reduced life expectancy for whom tight blood glucose control poses a high risk of the consequences of hypoglycaemia, for example, people who are at risk of falling, people who have impaired awareness of hypoglycaemia, and people who drive or operate machinery as part of their job for whom intensive management would not be appropriate, for example, people with significant comorbidities.	
dose titration	0	0.2191	2	When starting insulin therapy in adults with type 2 diabetes, use a structured programme employing active insulin dose titration that encompasses: injection technique, including rotating injection sites and avoiding repeated injections at the same point within sites continuing telephone support self-monitoring dose titration to target levels dietary understanding	When starting insulin therapy in adults with type 2 diabetes, use a structured programme employing active insulin dose titration that encompasses: injection technique, including rotating injection sites and avoiding repeated injections at the same point within sites continuing telephone support self-monitoring dose titration to target levels dietary understanding	
insulin detemir	0	0.2191	4	Consider switching to insulin detemir or insulin glargine from NPH insulin in adults with type 2 diabetes: who do not reach their target HbA1c because of significant hypoglycaemia or who experience significant hypoglycaemia on NPH insulin irrespective of the level of	Monitor adults with type 2 diabetes who are on a basal insulin regimen (NPH insulin, insulin detemir or insulin glargine ) for the need for short-acting insulin before meals (or a pre-mixed biphasic insulin preparation).	Consider switching to insulin detemir or insulin glargine from NPH insulin in adults with type 2 diabetes: who do not reach their target HbA1c because of significant hypoglycaemia or who experience significant hypoglycaemia on NPH insulin irrespective of the level of	Monitor adults with type 2 diabetes who are on a basal insulin regimen (NPH insulin, insulin detemir or insulin glargine ) for the need for short-acting insulin before meals (or a pre-mixed biphasic insulin preparation).	
insulin glargine	0	0.2191	4	Consider switching to insulin detemir or insulin glargine from NPH insulin in adults with type 2 diabetes: who do not reach their target HbA1c because of significant hypoglycaemia or who experience significant hypoglycaemia on NPH insulin irrespective of the level of	Monitor adults with type 2 diabetes who are on a basal insulin regimen (NPH insulin, insulin detemir or insulin glargine ) for the need for short-acting insulin before meals (or a pre-mixed biphasic insulin preparation).	Consider switching to insulin detemir or insulin glargine from NPH insulin in adults with type 2 diabetes: who do not reach their target HbA1c because of significant hypoglycaemia or who experience significant hypoglycaemia on NPH insulin irrespective of the level of	Monitor adults with type 2 diabetes who are on a basal insulin regimen (NPH insulin, insulin detemir or insulin glargine ) for the need for short-acting insulin before meals (or a pre-mixed biphasic insulin preparation).	
significant hypoglycaemia	0	0.2191	2	Consider switching to insulin detemir or insulin glargine from NPH insulin in adults with type 2 diabetes: who do not reach their target HbA1c because of significant hypoglycaemia or who experience significant hypoglycaemia on NPH insulin irrespective of the level of	Consider switching to insulin detemir or insulin glargine from NPH insulin in adults with type 2 diabetes: who do not reach their target HbA1c because of significant hypoglycaemia or who experience significant hypoglycaemia on NPH insulin irrespective of the level of	
target hba1c	0	0.1479	4	Consider relaxing the target HbA1c level (see recommendations and )	Consider switching to insulin detemir or insulin glargine from NPH insulin in adults with type 2 diabetes: who do not reach their target HbA1c because of significant hypoglycaemia or who experience significant hypoglycaemia on NPH insulin irrespective of the level of	Consider relaxing the target HbA1c level (see recommendations and )	Consider switching to insulin detemir or insulin glargine from NPH insulin in adults with type 2 diabetes: who do not reach their target HbA1c because of significant hypoglycaemia or who experience significant hypoglycaemia on NPH insulin irrespective of the level of	
active insulin	0	0.1095	2	When starting insulin therapy in adults with type 2 diabetes, use a structured programme employing active insulin dose titration that encompasses: injection technique, including rotating injection sites and avoiding repeated injections at the same point within sites continuing telephone support self-monitoring dose titration to target levels dietary understanding	When starting insulin therapy in adults with type 2 diabetes, use a structured programme employing active insulin dose titration that encompasses: injection technique, including rotating injection sites and avoiding repeated injections at the same point within sites continuing telephone support self-monitoring dose titration to target levels dietary understanding	
basal insulin	0	0.1095	2	Monitor adults with type 2 diabetes who are on a basal insulin regimen (NPH insulin, insulin detemir or insulin glargine ) for the need for short-acting insulin before meals (or a pre-mixed biphasic insulin preparation).	Monitor adults with type 2 diabetes who are on a basal insulin regimen (NPH insulin, insulin detemir or insulin glargine ) for the need for short-acting insulin before meals (or a pre-mixed biphasic insulin preparation).	
biphasic insulin	0	0.1095	2	Monitor adults with type 2 diabetes who are on a basal insulin regimen (NPH insulin, insulin detemir or insulin glargine ) for the need for short-acting insulin before meals (or a pre-mixed biphasic insulin preparation).	Monitor adults with type 2 diabetes who are on a basal insulin regimen (NPH insulin, insulin detemir or insulin glargine ) for the need for short-acting insulin before meals (or a pre-mixed biphasic insulin preparation).	
dietary understanding	0	0.1095	2	When starting insulin therapy in adults with type 2 diabetes, use a structured programme employing active insulin dose titration that encompasses: injection technique, including rotating injection sites and avoiding repeated injections at the same point within sites continuing telephone support self-monitoring dose titration to target levels dietary understanding	When starting insulin therapy in adults with type 2 diabetes, use a structured programme employing active insulin dose titration that encompasses: injection technique, including rotating injection sites and avoiding repeated injections at the same point within sites continuing telephone support self-monitoring dose titration to target levels dietary understanding	
injection sites	0	0.1095	2	When starting insulin therapy in adults with type 2 diabetes, use a structured programme employing active insulin dose titration that encompasses: injection technique, including rotating injection sites and avoiding repeated injections at the same point within sites continuing telephone support self-monitoring dose titration to target levels dietary understanding	When starting insulin therapy in adults with type 2 diabetes, use a structured programme employing active insulin dose titration that encompasses: injection technique, including rotating injection sites and avoiding repeated injections at the same point within sites continuing telephone support self-monitoring dose titration to target levels dietary understanding	
injection technique	0	0.1095	2	When starting insulin therapy in adults with type 2 diabetes, use a structured programme employing active insulin dose titration that encompasses: injection technique, including rotating injection sites and avoiding repeated injections at the same point within sites continuing telephone support self-monitoring dose titration to target levels dietary understanding	When starting insulin therapy in adults with type 2 diabetes, use a structured programme employing active insulin dose titration that encompasses: injection technique, including rotating injection sites and avoiding repeated injections at the same point within sites continuing telephone support self-monitoring dose titration to target levels dietary understanding	
insulin dose	0	0.1095	2	When starting insulin therapy in adults with type 2 diabetes, use a structured programme employing active insulin dose titration that encompasses: injection technique, including rotating injection sites and avoiding repeated injections at the same point within sites continuing telephone support self-monitoring dose titration to target levels dietary understanding	When starting insulin therapy in adults with type 2 diabetes, use a structured programme employing active insulin dose titration that encompasses: injection technique, including rotating injection sites and avoiding repeated injections at the same point within sites continuing telephone support self-monitoring dose titration to target levels dietary understanding	
insulin preparation	0	0.1095	2	Monitor adults with type 2 diabetes who are on a basal insulin regimen (NPH insulin, insulin detemir or insulin glargine ) for the need for short-acting insulin before meals (or a pre-mixed biphasic insulin preparation).	Monitor adults with type 2 diabetes who are on a basal insulin regimen (NPH insulin, insulin detemir or insulin glargine ) for the need for short-acting insulin before meals (or a pre-mixed biphasic insulin preparation).	
insulin regimen	0	0.1095	2	Monitor adults with type 2 diabetes who are on a basal insulin regimen (NPH insulin, insulin detemir or insulin glargine ) for the need for short-acting insulin before meals (or a pre-mixed biphasic insulin preparation).	Monitor adults with type 2 diabetes who are on a basal insulin regimen (NPH insulin, insulin detemir or insulin glargine ) for the need for short-acting insulin before meals (or a pre-mixed biphasic insulin preparation).	
insulin types	0	0.1095	2	Start insulin therapy for adults with type 2 diabetes from a choice of a number of insulin types and regimens:	Start insulin therapy for adults with type 2 diabetes from a choice of a number of insulin types and regimens:	
intolerance start	0	0.1095	0	
levels dietary	0	0.1095	2	When starting insulin therapy in adults with type 2 diabetes, use a structured programme employing active insulin dose titration that encompasses: injection technique, including rotating injection sites and avoiding repeated injections at the same point within sites continuing telephone support self-monitoring dose titration to target levels dietary understanding	When starting insulin therapy in adults with type 2 diabetes, use a structured programme employing active insulin dose titration that encompasses: injection technique, including rotating injection sites and avoiding repeated injections at the same point within sites continuing telephone support self-monitoring dose titration to target levels dietary understanding	
monitor adults	0	0.1095	4	Monitor adults with type 2 diabetes who are on a basal insulin regimen (NPH insulin, insulin detemir or insulin glargine ) for the need for short-acting insulin before meals (or a pre-mixed biphasic insulin preparation).	Monitor adults with type 2 diabetes who are on pre-mixed (biphasic) insulin for the need for a further injection of short-acting insulin befor	Monitor adults with type 2 diabetes who are on a basal insulin regimen (NPH insulin, insulin detemir or insulin glargine ) for the need for short-acting insulin before meals (or a pre-mixed biphasic insulin preparation).	Monitor adults with type 2 diabetes who are on pre-mixed (biphasic) insulin for the need for a further injection of short-acting insulin befor	
pre-mixed biphasic	0	0.1095	2	Monitor adults with type 2 diabetes who are on a basal insulin regimen (NPH insulin, insulin detemir or insulin glargine ) for the need for short-acting insulin before meals (or a pre-mixed biphasic insulin preparation).	Monitor adults with type 2 diabetes who are on a basal insulin regimen (NPH insulin, insulin detemir or insulin glargine ) for the need for short-acting insulin before meals (or a pre-mixed biphasic insulin preparation).	
repeated injections	0	0.1095	2	When starting insulin therapy in adults with type 2 diabetes, use a structured programme employing active insulin dose titration that encompasses: injection technique, including rotating injection sites and avoiding repeated injections at the same point within sites continuing telephone support self-monitoring dose titration to target levels dietary understanding	When starting insulin therapy in adults with type 2 diabetes, use a structured programme employing active insulin dose titration that encompasses: injection technique, including rotating injection sites and avoiding repeated injections at the same point within sites continuing telephone support self-monitoring dose titration to target levels dietary understanding	
self-monitoring dose	0	0.1095	2	When starting insulin therapy in adults with type 2 diabetes, use a structured programme employing active insulin dose titration that encompasses: injection technique, including rotating injection sites and avoiding repeated injections at the same point within sites continuing telephone support self-monitoring dose titration to target levels dietary understanding	When starting insulin therapy in adults with type 2 diabetes, use a structured programme employing active insulin dose titration that encompasses: injection technique, including rotating injection sites and avoiding repeated injections at the same point within sites continuing telephone support self-monitoring dose titration to target levels dietary understanding	
start insulin	0	0.1095	2	Start insulin therapy for adults with type 2 diabetes from a choice of a number of insulin types and regimens:	Start insulin therapy for adults with type 2 diabetes from a choice of a number of insulin types and regimens:	
structured programme	0	0.1095	2	When starting insulin therapy in adults with type 2 diabetes, use a structured programme employing active insulin dose titration that encompasses: injection technique, including rotating injection sites and avoiding repeated injections at the same point within sites continuing telephone support self-monitoring dose titration to target levels dietary understanding	When starting insulin therapy in adults with type 2 diabetes, use a structured programme employing active insulin dose titration that encompasses: injection technique, including rotating injection sites and avoiding repeated injections at the same point within sites continuing telephone support self-monitoring dose titration to target levels dietary understanding	
support self-monitoring	0	0.1095	2	When starting insulin therapy in adults with type 2 diabetes, use a structured programme employing active insulin dose titration that encompasses: injection technique, including rotating injection sites and avoiding repeated injections at the same point within sites continuing telephone support self-monitoring dose titration to target levels dietary understanding	When starting insulin therapy in adults with type 2 diabetes, use a structured programme employing active insulin dose titration that encompasses: injection technique, including rotating injection sites and avoiding repeated injections at the same point within sites continuing telephone support self-monitoring dose titration to target levels dietary understanding	
telephone support	0	0.1095	2	When starting insulin therapy in adults with type 2 diabetes, use a structured programme employing active insulin dose titration that encompasses: injection technique, including rotating injection sites and avoiding repeated injections at the same point within sites continuing telephone support self-monitoring dose titration to target levels dietary understanding	When starting insulin therapy in adults with type 2 diabetes, use a structured programme employing active insulin dose titration that encompasses: injection technique, including rotating injection sites and avoiding repeated injections at the same point within sites continuing telephone support self-monitoring dose titration to target levels dietary understanding	
